

## AUTHOR INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E, and a number.

Page references to Supplement 1 (April 2000) and Supplement 2 (June 2000) are preceded, respectively, by S1: and S2:.

- Abbott, K.C., 237  
Abrass, C.K., 544  
Abt, A.B., 533  
Abu-Alfa, A.K., 1076  
Adams, J.E., 227  
Afzal, A.R., 211  
Agodoa, L., 157, 352  
Agodoa, L.Y.C., 80  
Agraharkar, M., 319  
Ahmad, S., 477, 493  
Ahuja, T.S., 884  
Albizuia, R., 137  
Alegre, R., 141  
Allen, A.C., 551  
Alon, U.S., 1111  
Alt, P.S., S1:141  
Anastasio, P., 1144  
Anderson, R.J., 1127  
Anderson, S., 923  
André, M.B., 839  
Andreoli, S.P., S1:31  
Andrés, A., 141  
Andresdottir, M.B., 2:E6  
Andreucci, M., 448  
Andreucci, V.E., 448  
Argyle, R., 112  
Arisz, L.A., 819  
Arora, N., 301  
Arruda, J.A.L., 739  
Arumugam, R., 301  
Asaka, M., 6:E31  
Aschauer, M., 529  
Ashby, V.B., 80  
Ashford, R.G., 796  
Ashmore, S.D., 827  
Asif, A., 3:E10  
Assmann, K.J.M., 2:E6  
Ates, K., 1207  
Atkins, C., S1:19  
Atkins, R.C., 418  
Azzopardi, J., 708
- Bahlmann, F., 21  
Bahnner, U., 347  
Bailie, G.R., 1  
Balabanian, M., 963  
Barats, M.S., 963  
Bargman, J.M., 506  
Barrios, R., 4:E15
- Bastani, B., 146  
Beach, K., 477  
Becker, B.N., 653  
Becker, Y.T., 653  
Bellin, M-F., 745  
Bellovich, K., 606  
Beltramo, D., 941  
Bengal, R., 930  
Benini, R., 1155  
Bennett, W.M., 333  
Benz, R.L., 1052  
Berden, J.H.M., 845  
Berger, R., 1149  
Berl, T., 6:xlvii-l  
Berland, Y., 13  
Bernardini, J., 1104  
Bia, M.J., 1076  
Birk, C.G., 1089  
Bitzan, M.M., 354  
Blagg, C.R., 493  
Blake, P.G., 506  
Blake, R., 506  
Block, G.A., 1226  
Blowey, D.L., 1111  
Boeschoten, E.W., 69  
Böhmg, G.A., 667  
Bolton, W.K., 266  
Border, W.A., 773  
Borucki, M., 884  
Bos, W.J.W., 819  
Bosch, J.P., 2:xlvi-xlviii  
Boulton-Jones, J.M., 852  
Bourgoignie, J., 5:E24  
Bouvier, C., 13  
Boyle, P., 157, 352  
Braam, B., 202  
Braden, G.L., 878  
Brand, J.L., S1:81  
Brazy, P.C., 653  
Brezina, M., 122, 832  
Brier, M.E., 89  
Briggs, D., 157, 352  
Briggs, W., 282  
Brophy, P.D., 958  
Brosnahan, G.M., 427  
Brown, W.W., S1:3  
Bruin, S., 819  
Bryant, J.L., 408  
Buccianti, G., 157, 352
- Buchalter, M., 753  
Budde, K., 3:E12  
Bühler, M., 624  
Bunchman, T.E., 958  
Burkart, J.M., 506
- Caglioti, A., 448  
Cain, J.A., 275  
Caldeira, F.E.R., 839  
Callan, R., 493  
Calleja, Y., 606  
Cameron, J.I., 629  
Campbell, G.A., 319  
Cao, P.G., 211  
Cao-Huu, T., 5:E21  
Capodicasa, L., 1144  
Carey, S., 482  
Caridi, G., 44  
Carlson, L., 482  
Carreiro, A., 137, 141  
Carroll, L.E., 533  
Cartwright, J. Jr., 4:E15  
Caslake, M.J., 852  
Cesana, B., 1135  
Chadha, V., 1111  
Chan, T.M., 644  
Chang, J-M., 189  
Chang, S-H., 313  
Chapman, A., 35  
Chapman, A.B., 427  
Charney, D., 173  
Charney, D.A., 1193  
Chau, K.F., 660  
Chayama, K., 1186  
Chen, C-H., 52  
Chen, G., 408  
Chen, H-C., 189  
Cheng, C-H., 52  
Chertow, G.M., 557, 1044, 6:E30  
Chevalier, R.L., 775  
Chin, W.D.N., 802  
Choi, P.C.L., 392  
Choudhury, D., 365  
Chrystyn, H., 827  
Ciardi, M.R., 44  
Cirillo, E., 1144  
Clase, C.M., 500  
Claudon, M., 5:E21  
Clayman, R.V., 720  
Coffin, R., 275

- Cohen, G., 1117  
 Cohen, J., 58  
 Cole, J.J., 493  
 Cole, M.J., 122  
 Coles, G.A., 112  
 Colindres, R.E., 695  
 Collins, A.J., 244  
 Collins, B.H., 653  
 Comi, N., 448  
 Comper, W.D., 418  
 Conlon, P.J., 573  
 Conrad, A., 832  
 Constantini, E.G., 244  
 Cormier, L., 5:E21  
 Coroneos, E., 4:E15  
 Cosio, F.G., 749  
 Couser, W.G., 5:E23  
 Covic, A., 361, 617  
 Covic, M., 617  
 Covinsky, K.E., 275  
 Cruz, D., 1076  
 Cueto-Manzano, A.M., 227  
 Cushing, H., 4:E16  
 Cusumano, A., 408  
 Cynke, E., 537
- D'Agata, E. M.C., 1083  
 D'Agata, E.M.C., 64  
 D'Agati, V.D., 777  
 Dagnino, M., 44  
 Dalleska, F., 244  
 Daly, M.J., 827  
 Daniel, L., 13  
 Dasgupta, M.K., 506  
 Datta, S.K., 992  
 Daugirdas, J.T., 80  
 Davies, S.J., 753  
 Davis, J., S1:76  
 De Haan, R.J., 69  
 Deicher, R., 1117  
 Deighan, C.J., 852  
 Dekker, F.W., 69  
 Delano, B.G., 506  
 Delmez, J.A., 150  
 De Mattos, A.M., 333  
 DeMayo, F., 362  
 De Meer, K., 1149  
 De Nicola, L., 448  
 Deray, G., 745  
 De Sain-van der Velden, M.G.M., 1149  
 De Santo, N.G., 1144  
 Devins, G.M., 629  
 Diaz-Buxo, J.A., 293  
 Diego, J., 3:E10, 5:E24  
 Diehl, L.F., 237  
 Diemont, W.L., 845  
 Disney, A.P.S., 157, 352  
 Dixit, V., 122, 832  
 Doe, N., 4:E15  
 Doesburg, W.H., 845
- Dominguez-Gil, B., 137  
 Domínguez-Gil, B., 141  
 Dossetor, J.B., 1002  
 Druml, W., 667  
 Dunea, G., 739  
 Dunn, M.D., 720  
 Dunn, M.J., 976
- Ebben, J.P., 244  
 Ecdet, T., 427  
 Echenagusia, A., 5:E26  
 Edelstein, C.L., 427  
 Eknoyan, G., S1:69  
 El Asmar, B., 362  
 Elbahnasy, A.M., 720  
 El-Ghoroury, M., 606  
 Elli, A., 1135  
 Endo, M., 401  
 Eppel, G.A., 418  
 Eras, J., 937  
 Erekul, S., 1207  
 Ertug, A.E., 1207  
 Ertürk, U., 1207  
 Escrivá, A., 137  
 Evans, J., 904  
 Everson, S.E., 244  
 Exner, M., 667, 1117
- Fabrizi, F., 122, 832  
 Faict, D., 112  
 Falk, R.J., 695, 1166  
 Falkenhain, M.E., 749  
 Fatica, R.A., 526  
 Fava, S., 708  
 Federico, P., 1144  
 Feehally, J., 551  
 Ferrer, C.I., 941  
 Ferreras, I., 5:E26  
 Fine, A., 506  
 Finkel, K.W., 1:E2, 2:E5, 3:E8, 4:E14,  
     5:E18, 6:E29  
 Finkelstein, F., 506  
 Finkelstein, F.O., 638  
 Finkelstein, S.H., 638  
 Flis, R.S., 777  
 Floege, J., 21  
 Fogo, A., 1:E1, 2:E4, 3:E7, 4:E13,  
     5:E17, 6:E28, 997  
 Fogo, A.B., 179, 1242  
 François, M., 745  
 Frangiosa, A., 1144  
 Frankel, W.L., 749  
 Franklin, S.C., 150  
 Freedman, B.I., 35  
 Freemont, A.J., 227  
 Frey, F.J., 624  
 Friedman, A., 653  
 Frimat, L., 5:E21  
 Fu, P., 257  
 Fujiano, G., 448  
 Fujimoto, K., 863
- Fujita, T., 401  
 Furth, S.L., 282
- Gadallah, M.F., 301  
 García, N.H., 941  
 Gardner, J., 958  
 Gaucher, O., 5:E21  
 Gellens, M., 146  
 Gellert, R., 157, 352  
 George, A.L. Jr., S1:160  
 Georgitis, J.W., 354  
 Germain, M.J., 878  
 Gesualdo, L., 726  
 Gherardi, G., 1155  
 Ghiggeri, G.M., 44  
 Ghio, L., 44  
 Gibney, R.T.N., 802  
 Ginevri, F., 44  
 Giorgi, R., 13  
 Girndt, M., 95, 611  
 Gitnick, G., 122, 832  
 Gitomer, J.J., 1:E2, 2:E5, 3:E8, 4:E14,  
     5:E18, 6:E29  
 Givner, L.B., 354  
 Glasscock, R.J., S1:90  
 Gokal, R., 227  
 Gokhale, S., 319  
 Goldsmith, D.J.A., 361, 617  
 Gonick, H.C., 963  
 Gonwa, T.A., S1:153  
 Gopal, H., 969  
 Grady, J., 884  
 Grandaliano, G., 726  
 Grantham, J.J., 221  
 Green, K., 64  
 Grimm, E.M., 1:E2, 2:E5, 3:E8,  
     4:E14, 5:E18, 6:E29  
 Group for the Water and Electrolyte  
     Balance Study in CAPD, 515  
 Grover, F.L., 1127  
 Guardia, J.A., 5:E24  
 Guh, J.-Y., 189  
 Gupta, A., 360  
 Gusmano, R., 44
- Haag-Weber, M., 1117  
 Haas, D.W., 64  
 Haas, M., 433  
 Haddad, F., 362  
 Hamm, L., S1:1  
 Hammermeister, K.E., 1127  
 Hanaoka, M., 458  
 Hara, M., 1186  
 Hara, S., 761, 1186  
 Harada, T., 896  
 Hashimoto, K., 889  
 Hasnain, M., 739  
 Hassan, H., 146  
 Hateboer, N., 753  
 Hattersley, A.T., 708  
 Haubitz, M., 21

- Hauk, M., 105  
 Hayano, S., 323  
 Hayashi, T., 194, 250  
 Hayek, G., 362  
 Hegde, A., 1039  
 Heidenheim, P., 506  
 Heidland, A., 347  
 Helderman, H., 154  
 Helderman, J.H., 1242  
 Helmandollar, A.W., 266  
 Henderson, L.W., S1:106  
 Henderson, W.G., 1127  
 Hermann, J.A., 282  
 Hernández, E., 141  
 Herrero, J.C., 137  
 Herzenberg, A.M., 5:E25  
 Herzog, C.A., 1217  
 Hewan-Lowe, K., 1:E3  
 Hewan-Lowe, K., 783  
 Hickman, R., 477  
 Hilbrands, L.B., 2:E6  
 Hirsch, D.J., 588  
 Hisada, Y., 169  
 Ho, K.K.L., 392  
 Hogan, S.L., 695  
 Hollander, W.M., 884  
 Holley, J.L., 1061  
 Holmes, C.J., 112  
 Holzer, H., 529  
 Hori, M., 194, 250, 713  
 Hörl, W.H., 130, 667, 1117  
 Horn, K., 4:E15  
 Horn, R.G., 1242  
 Hosoya, T., 465  
 Hovick, E.T., 1052  
 Hsu, H.-C., 313  
 Hubert, J., 5:E21  
 Hull, C.M., 5:E23  
 Hutchison, A.J., 227  
 Hwang, S.-J., 189
- Ichikawa, I., 5:lviii–lx  
 Imai, E., 194, 250, 713  
 Imai, H., 3:E9, 3:E11  
 Imai, T., 761  
 Ingram, A.J., 500  
 Inoue, S., 761  
 Iodice, C., 448  
 Ishikawa, I., 6:E31, 216, 1072  
 Ishikawa, Y., 216  
 Ishiwaru, K., 5:E22  
 Iskander, S.S., 354  
 Itoh-Ihara, T., 889  
 Izumi, M., 713  
 Izzedine, H., 745
- Jaar, B.G., 282  
 Jaber, B.L., 980  
 Jager, K.J., 69  
 Janigan, D.T., 588  
 Janssen, U., 21
- Jaradat, M., 4:E16  
 Jeffery, S., 211  
 Jenette, J.C., 1166  
 Johnson, A.M., 427  
 Johnson, C.A., 1  
 Jones, C.A., 80  
 Jones, C.H., 827  
 Jones, E., 157, 352  
 Jones, S., 112  
 Jost, M.-C., 537  
 Joy, M.S., 695  
 Julian, B.A., 555  
 Juncos, L.I., 941
- Kalra, P.A., 573  
 Kambham, N., 777  
 Kaneda, H., 863  
 Kang, S.-H., 923  
 Kanno, Y., 408  
 Karatan, O., 1207  
 Karsou, S.A., 980  
 Kasahara, M., 221  
 Kasahara, Y., 863  
 Kasai, K., 465  
 Katoh, N., 465  
 Katori, H., 761, 1186  
 Katz, J., 629  
 Kaul, H., 95, 611  
 Kawaguchi, Y., 465, 515, 1072  
 Kawakatsu, H., 5:E22  
 Kawamura, T., 889, 896  
 Kawasaki, C., 323  
 Kayser, G., S1:1  
 Kayser, G.A., 469, 1149  
 Keane, W.F., S1:97  
 Kenefick, T.M., 923  
 Kessler, M., 5:E21  
 Keur, I., 819  
 Keven, K., 1207  
 Khairullah, Q., 606  
 Khan, S., 1039  
 Kiaii, M., 5:E25  
 Kimmel, P.L., S1:132, 1221  
 Kirschbaum, B., 1068  
 Kitabayashi, A., 3:E11  
 Kitagawa, S., 6:E31  
 Kitamura, A., 761, 1186  
 Klassen, G.A., 588  
 Kliger, A.S., 638  
 Knostman, J.D., 5:E23  
 Kobayashi, Y., 896  
 Kodama, T., 3:E9  
 Koenig, K.G., 266  
 Köhl, J., 21  
 Köhler, H., 95, 105, 611  
 Koizumi, S., 863  
 Kojima, K., 1175  
 Komatsu, H., 5:E22  
 Komatsuda, A., 3:E9, 3:E11  
 Konel, S., 227  
 Kooman, J.P., 5:E19
- Koomans, H.A., 202  
 Kopp, J.B., 408, 1166  
 Kopple, J.D., S1:1, S1:93  
 Korbet, S.M., 506, 904  
 Kovarik, J., 667  
 Kravet, S., 173  
 Krediet, R.T., 69, 819  
 Krepinsky, J., 500  
 Krisher, J., 35  
 Krisper, P., 529  
 Kshirsagar, A.V., 695  
 Kubo, H., 465  
 Kuhlmann, M.K., 105  
 Kulik, W., 1149  
 Kumano, K., 515  
 Kundu, G., 362  
 Kuo, H.-T., 189  
 Kurtzman, N.A., 327  
 Kusaka, M., 221  
 Kutsogiannis, D.J., 802  
 Kuzuhara, K., 761  
 Kyriazis, J., 1096
- Lafayette, R., 166  
 Lai, K.B., 644  
 Lai, K.N., 644  
 Lai, Y.-H., 189  
 Lai Mac-Moune, F., 392  
 Lam, C.W.K., 644  
 Lan, H.Y., 418  
 Lan, J.-L., 52  
 Laski, M.E., 1224  
 Lazarou, L.P., 753  
 Lazarus, J.M., 293, 598  
 Le, L., 319  
 LeBrun, C.J., 237  
 Lederer, E., 1238  
 Leitner, G., 529  
 Lemmens, W.A.J.G., 845  
 Lengler, S., 95  
 Leung, C.B., 392  
 Leung, J.C.K., 644  
 Leunissen, K.M.L., 5:E19  
 Levey, A.S1:., S1:117  
 Levi, M., 365  
 Levin, N.W., S1:69  
 Levine, R.A., 469  
 Lew, N.L., 293, 598  
 Lewis, E.J., 904  
 Lewis, J.B., 154  
 Li, C.S., 660  
 Li, F.K., 644  
 Li, P.K.T., 392  
 Li, Z., 598  
 Lian, J.-D., 52  
 Lien, Y.-H.H., 539  
 Lin, C.-H., 313  
 Litalien, C., 29  
 Liu, J.S., 216  
 López-Baena, J.A., 5:E26  
 Lorentz, W.B., 354

- Losito, A., 211  
 Lowefels, A.B., 157, 352  
 Lowrie, E.G., 293, 598  
 Lugon, J.R., 839  
 Lui, S.F., 392
- Ma, J.Z., 244  
 Maccario, M., 1135  
 McClellan, W.M., 35  
 McConnell, M., 852  
 McCredie, M., 157, 352  
 McCusker, F.X., 506  
 MacDonald, A.S., 588  
 McDougall, E.M., 720  
 Mackenzie, R.K., 112  
 McKinley, M., S1:19  
 McMurray, S.D., 506  
 McNeil, B.J., 1044  
 Madaio, M.P., 992  
 Madhan, K.K., 1212  
 Madi-Jebara, S., 362  
 Maeda, K., 1072  
 Magil, A.B., 5:E25  
 Mahnensmith, R.L., 1076  
 Maisonneuve, P., 157, 352  
 Mamouna, A., 1096  
 Mantadilok, V., 469  
 Manton, W.I., 963  
 Mariscalco, M.M., 29  
 Markowitz, G.S., 777  
 Martin, P., 122, 832  
 Martin, S. R., 1089  
 Maschio, G., 4:liv-lvi  
 Mason, N.A., 1  
 Matos, J.P.S., 839  
 Matsuda, J., 221  
 Matsui, K., 1175  
 Matsuo, T., 458  
 Matsushita, M., 401  
 Matsushita, Y., 761, 1186  
 Mawer, B., 227  
 MaWhinney, S., 1127  
 Mayers, I., 802  
 Mazza, G., 448  
 Meehan, S.M., 433  
 Meissner, M., 477  
 Melissant, C. F., 1149  
 Mercadal, L., 745  
 Merkus, M.P., 69  
 Mestecky, J., 555  
 Meuleman, E.J.H., 845  
 Meyer, T.W., 674  
 Miki, K., 3:E9  
 Miller, J., 3:E10  
 Miller, S.B., 150  
 Milutinovic, J., 950  
 Miura, A.B., 3:E9, E11  
 Moe, S., 4:E16  
 Mohler, J.H., 533  
 Moles, K., 301  
 Molino, D., 1144
- Molony, D.A., 1:E2, 2:E5, 3:E8,  
 4:E14, 5:E18, 6:E29  
 Monno, R., 726  
 Montagnino, G., 1135  
 Moore, J. Jr., 1039  
 Moore, K.D., 796  
 Moore, L.W., S1:19  
 Morales, E., 137, 141  
 Moriggi, M., 381  
 Moritz, T.E., 1127  
 Morrison, L., 606  
 Morton, A.R., 306  
 Mosconi, L.M., 381  
 Moseley, A., 112  
 Mount, D.B., 1083  
 Mouratoff, J.G., 557  
 Mousa, M., 122  
 Mueller, B.A., 310  
 Muiño, J.C., 941  
 Mukherjee, A.B., 362  
 Mulhern, J.G., 878  
 Munir, I., 950  
 Murer, L., 44  
 Muso, E., 889  
 Myll, J., 482
- Nadasdy, T., 1193  
 Nagahama, K., 1186  
 Nagao, S., 221  
 Nagaraj, S.K., 354  
 Nagase, M., 1175  
 Nagatoya, K., 713  
 Nagy, M., 1104  
 Nakai, S., 1072  
 Nakamoto, Y., 3:E11  
 Nakamura, H., 713  
 Nakanishi, I., 194  
 Nakano, H., 465  
 Nakayama, M., 465  
 Nakazawa, T., 6:E31, 216  
 Nash, S.V., 878  
 Nassar, G., 1193  
 Neilson, E.G., S1:160  
 Nergizoglu, G., 1207  
 Neumayer, H-H., 3:E12  
 Newstead, C.G., 827  
 Nieto, F.J., 812  
 Nikolic-Paterson, D.J., 418  
 Nimura, T., 3:E11  
 Nishi, R., 323  
 Nishida, M., 5:E22  
 Noble, N.A., 773  
 Nogueira, M., 4:E15  
 Nomura, M., 458  
 Normand, S.T., 1044  
 Novak, J., 555  
 Nudo, S.A., 796  
 Nüesch, R., 537  
 Nylander, W., 997  
 Nzerue, C.M., 1:E3, 783
- Oberley, E.T., S1:141  
 O'Brien, M., 1127  
 Oderinde, A., 1:E3  
 Ogiso, N., 221  
 Ohi, H., 401  
 Ohswa, I., 401  
 Ohta, K., 863  
 Ohtani, H., 3:E9, E11  
 Okada, N., 194, 250  
 Olson, J.L., 557, 674  
 Olyaei, A.J., 333  
 O'Neill, W.C., 978, 1021  
 Ono, T., 889  
 Orhan, D., 1207  
 O'Riordan, E., 573  
 Ortel, T.L., 796  
 Orth, S.R., 767  
 Ortúñu, T., 137  
 O'Shea, M.H., 878  
 Otagiri, M., 323  
 Ouseph, R., 89  
 Ovworue, C., 173  
 Oyama, A., 889  
 Oyama, T.T., 923  
 Oyama, Y., 3:E11
- Pacheco, D., 5:E26  
 Packard, C.J., 852  
 Painter, P., 482  
 Parente, B., 211  
 Paukesakon, P., 1242  
 Paul, S.M., 482  
 Paulson, W.D., 973, 1089  
 Paun, M., 477  
 Pece, R., 954  
 Pegeraro, A.A., 739  
 Pellissier, J-F., 13  
 Peracha, W., 739  
 Perazella, M.A., 937, 1076  
 Pereira, B.J.G., 980  
 Perfumo, F., 44  
 Perna, A., 1155  
 Peterson, D.D., 1052  
 Pfister, M., 624  
 Phillips, C., 4:E16  
 Piaggio, G., 44  
 Pieper, D., 606  
 Pintar, T.J., 653  
 Piraino, B., 1104  
 Pirsch, J.D., 653  
 Plante, C.L., S1:45  
 Plett, C., 477  
 Pobes, A., 954  
 Poffenbarger, T., 681  
 Polito, A., 832  
 Pollastro, R.M., 1144  
 Polo, J.R., 5:E26  
 Ponticelli, C., 1135  
 Port, F.K., 80, 1226  
 Portis, A.J., 720  
 Portman, R., 681

- Postler, G., 871  
 Powe, N.R., 282  
 Powers, K.M., 266  
 Prag, K.A., 310  
 Praga, M., 137, 141  
 Pressman, M.R., 1052  
 Proulx, F., 29  
 Provenzano, R., 606  
 Provost, A.P., 202  
 Pu, K., 112
- Quan, S., 832
- Rabb, H., 871  
 Rabelink, T.J., 1149  
 Racusen, L., 173  
 Rahman, M., 257  
 Raj, D.S.C., 365  
 Rajaraman, S., 319, 884  
 Ram, S.J., 1089  
 Ranginwala, N., 739  
 Ranieri, E., 726  
 Ravine, D., 753  
 Regalado, M., 687  
 Regele, H., 667  
 Reichlin, M., 904  
 Rembold, S.M., 839  
 Remuzzi, A., 381  
 Remuzzi, G., 381, 1155  
 Renoult, E., 5:E21  
 Revelo, M.P., 1242  
 Riegel, W., 105  
 Riley, L.J. Jr., 783  
 Ritz, E., 767  
 Rodriguez, M., 954  
 Rodriguez-Iturbe, B., 1:xvi-xlviii  
 Rohde, R.D., 904  
 Romero, M., 941  
 Rosenkranz, A.R., 130  
 Roth, D., 3:E10  
 Rothenberg, S., 963  
 Rothstein, M., 720  
 Rubin, J.M., 526  
 Ruggenenti, P., 381, 1155
- Sadler, J.H., 51:141  
 Säemann, M.D., 667  
 Saingra, Y., 13  
 Saito, I., 465  
 Saito, Y., 216  
 Sakai, S., 465  
 Sakamoto, K., 6:E31  
 Sakarcan, A., 5:E20  
 Sambuelli, R.H., 941  
 Sands, J.J., 796  
 Sangalli, F., 381  
 Sankarasubbayan, S., 1061  
 Sano, K., 465  
 Sarnak, M.L., 51:117  
 Saruta, T., 458  
 Sayasama, S., 889
- Sawada, T., 5:E22  
 Saxena, R., 749  
 Schädeli, F., 624  
 Schaffner, W., 64, 1083  
 Schena, F. P., 726  
 Schenk, P., 130  
 Schievink, W.I., 40  
 Schneditz, D., 529  
 Schötschel, R., 3:E12  
 Schreiner, G.E., 51:37  
 Schrier, R.W., 427  
 Schulman, G., 64  
 Schwartz, M.M., 904  
 Scott, K., 539  
 Scott, M.K., 310  
 Seco, M., 954  
 Sedmak, D.D., 749  
 Sehgal, A.R., 257, 275, 51:148  
 Seidman, A., 1039  
 Seidman, E., 29  
 Seki, H., 863  
 Seno, A., 863  
 Sepe, J., 1144  
 Sester, M., 95, 611  
 Sester, U., 95, 611  
 Sethi, G. K., 1127  
 Shahinian, V., 884  
 Shalhav, A.L., 720  
 Shappell, H.W., 997  
 Shappell, S., 4:E15  
 Shaykh, M., 739  
 Shek, C.C., 660  
 Sherrard, D.J., 969  
 Shigematsu, T., 465  
 Shoji, T., 194, 250  
 Shrivastav, S., 408  
 Shroyer, A.L., 1127  
 Shu, K.-H., 52  
 Silva, L. R., 1044  
 Silver, M.R., 275  
 Simckes, A.M., 1111  
 Simon, D., 1076  
 Singer, M.A., 306  
 Singh, A.K., 739  
 Sklar, A.H., 969  
 Smith, M.C., 257  
 Smoyer, W.E., 958  
 Soleimani, M., 871  
 Sollinger, H.W., 653  
 Sorof, J.M., 681  
 Soucie, J.M., 35  
 Sowinski, K.M., 310  
 Spargo, B.H., 433  
 Spitali, L., 1144  
 Spósito, M., 812  
 Stamatiadis, D., 1096  
 Steinberg, E.P., 51:69  
 Steinman, T.I., 770  
 Stellato, D., 1144  
 Stewart, J.H., 157, 352  
 Stigant, C.E., 58
- Strandness, D.E. Jr., 477  
 Sugaya, T., 169  
 Sugiura, T., 713  
 Suri, D.L., 674  
 Suzuki, A., 194, 250  
 Suzuki, S., 896  
 Suzuki, Y., 896  
 Symmans, P., 1212  
 Szeto, C.C., 392
- Tagami, T., 761, 1186  
 Takagawa, R., 761  
 Takahashi, H., 221  
 Takahashi, Y., 458  
 Takazoe, K., 418  
 Takemoto, F., 761, 1186  
 Tamai, M., 5:E22  
 Tanawattanacharoen, S., 1166  
 Tang, N.L.S., 392  
 Tarantino, A., 1135  
 Tayeb, J.S., 606  
 Tenenbein, M., 958  
 Tenney, F., 5:E20  
 Te Strake, L., 1212  
 Thayer, V., 1083  
 Thompson, M.M., 923  
 Tiesenhausen, K., 529  
 To, K.F., 392  
 Togawa, M., 194, 250  
 Tokumoto, J., 557  
 Toma, T., 863  
 Tomana, M., 555  
 Tomino, Y., 896  
 Tomlanovich, S.J., 674  
 Tomosugi, N., 6:E31, 216  
 Topley, N., 112  
 Toral, C., 3:E10  
 Torres, V.E., 40, 547, 930  
 Tostivint, I., 745  
 Traindl, O., 130  
 Truong, L., 1193  
 Truong, L.D., 4:E15  
 Tsai, J-C., 189  
 Tsai, J-H., 189  
 Tsubakihara, Y., 194, 250  
 Tsukamoto, Y., 458  
 Tulunay, O., 1207  
 Turgeon, J.P., 29
- Ubara, Y., 761, 1186  
 Ucci, A.A. Jr., 878  
 Uehlinger, D.E., 624  
 Uekihara, S., 323  
 Uflacker, R., 950
- Vamvakas, S., 347  
 VanBuren, D., 997  
 Van der Merwe, W., 1212  
 Van der Sande, F.M., 5:E19  
 Vanherwegen, J-L., 330  
 Van Olden, R.W., 819

- Vega, D., 5:E26  
 Veis, J.H., 1039  
 Vendramin, G., 381  
 Ventura, J.E., 812  
 Versepuit, G.H., 202  
 Vijayan, A., 150  
 VillaNueva, C.B., 1127  
 Vinson, S., 122  
 Vivera, M., 58  
 Volcy, J., 1:E3  
 Volmar, K., 173  
 Vruggink, P.A., 845  
 Wada, T., 863  
 Waiser, J., 3:E12  
 Wakui, H., 3:E9  
 Wang, A.Y.M., 392  
 Wang, Z., 871  
 Warady, B.A., 1111  
 Ward, J., 362  
 Ward, M.M., 915  
 Ward, R. A., 89  
 Watkins, P.J., 708  
 Watschinger, B., 667  
 Weening, J.J., 202  
 Weidner, M., 1242  
 Weitzel, W., 526  
 Welbourne, T.C., 365  
 Welch, P.G., 237  
 Wesseling, K.H., 819  
 Wesson, D.E., 3:lii-liv, 687  
 Westerhof, N., 819  
 Wetzels, J.F.M., 2:E6  
 Whiteside, C., 629  
 Wijdicks, E.F.M., 40  
 Wilkowski, M.J., 266  
 Williams, J.D., 112  
 Wit, E.J.C., 433  
 Wolfe, R.A., 80, 157, 352  
 Wölfl, G., 130  
 Woltmann, D., 526  
 Wong, K.M., 660  
 Wong, T.Y.H., 392  
 Work, J., 1089  
 Wu, M-J., 52  
 Wuert, D.B., 638  
 Wyckoff, S.J., S1:49  
 Yachie, A., 863  
 Yamada, A., 761, 1186  
 Yamaguchi, A., 3:E11  
 Yamaguchi, T., 221  
 Yamamoto, H., 465  
 Yang, C.-S., 313  
 Yang, S., 687  
 Yashiro, M., 889  
 Yazigi, A., 362  
 Yeun, J.Y., 469  
 Yokata, M., 1186  
 Yokota, M., 761  
 Yokoyama, H., 863  
 Yoshida, H., 896  
 Yoshida, I., 930  
 Yuan, C.M., 237  
 Yum, M-N., 4:E16  
 Yurik, T., 6:E31  
 Zabetakis, P.M., 506  
 Zaltzman, J.S., 58  
 Zapczynski, M., 1089  
 Zhang, H., 293  
 Zhang, Z., 362  
 Zheng, F., 362  
 Zimmerli, W., 537  
 Zimmerman, S.W., 506  
 Zlabinger, G.J., 667  
 Zwirner, J., 21

## SUBJECT INDEX

**Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon and page numbers.**

**Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.**

**Page references to Supplement 1 (April 2000) and Supplement 2 (June 2000) are preceded, respectively, by S1: and S2:.**

- Abstracts, from 9th Annual Clinical Nephrology Meeting, 4:A1-A29  
 ACE gene polymorphisms. *See* Angiotensin-converting enzyme gene polymorphisms  
 ACEi. *See* Angiotensin-converting enzyme inhibitors  
 Acetic dialysate, dialysis dose and, 493-499  
 Acid-base status  
 cocaine-induced imbalance, 789  
 management guidelines  
 adult, S2:38-39  
 pediatric, S2:107-108  
 Acidemia, treatment, S2: 38-39  
 Acidosis, metabolic. *See* Metabolic acidosis  
 Activated charcoal, for diethylene glycol poisoning, 958-962  
 Active transport inhibitor, for lead, in uremic plasma, 963-968  
 Acute illness, during maintenance dialysis  
 energy intake and, S2:51-53  
 protein intake and, S2:51-53  
 Acute phase response activation, in IgA nephropathy, 21-28  
 Acute renal failure (ARF)  
 cocaine-associated, 783-795  
 COX-2 inhibitor associated, 937-940  
 diagnosis, Doppler ultrasound for, 713-719  
 etiology/outcome in elderly, 433-447  
 with interstitial nephritis in AIDS, 557-561  
 noni juice-induced hyperkalemia and, 310-311  
 normeperidine neurotoxicity treatment and, 146-149  
 outcome after cardiac valve surgery and, 1127-1134  
 outcome variables, intermittent hemodialysis and, 980-991  
 pediatric, peritoneal dialysis catheter choice for, 1111-1116  
 potassium excretion impairment in, 871-877  
 renal biopsy, 448-457

- secondary to hematuria and tubular necrosis, 533–536  
ultrasonography, 1021–1039
- Acute tubular necrosis (ATN)  
differential diagnosis, Doppler ultrasound for, 713–719  
etiology/outcome, in elderly, 433–447  
ultrasonography, 1021–1039
- Adequacy  
impact of intermittent hemodialysis variables on, 980–991  
increased dialysate flow rate and, 05–111  
Netherlands Cooperative Study on, 69–79  
peritoneal dialysis  
multicenter cross-sectional study of, 515–525  
in U.S. vs. Canada, 506–514  
with two parallel dialyzers, 266–274
- Adjusted edema-free body weight, maintenance dialysis, S2:36–37
- ADPKD. *See* Autosomal dominant polycystic kidney disease
- Advanced glycation end products (AGEs), renal effects, 365–380
- Age/aging  
blood pressure in hemodialysis and, 257–265
- AIDS interstitial nephritis, with acute renal failure, 557–561
- Air pollution, MPO-ANCA-associated angitis/nephritis and, 889–895
- Albumin, serum  
ACE inhibition in diabetic vs. nondiabetic chronic renal disease and, 695–707  
low levels, CRP and, 469–476  
measurement methods, S2:66  
mortality prediction in ESRD with sleep disorders and, 1052–1061  
nutritional status in maintenance dialysis and, S2:20–21  
outcome prediction in chronic dialysis, 69–79  
processing  
in anti-glomerular basement membrane glomerulonephritis, 418–426  
in anti-Thy1 nephritis, 418–426
- Albuminuria  
absence, glomerular filtration rate and, 1144–1148  
diagnosis, fluorescent dye method vs. radioimmunoassay for, 739–744  
in progressive renal disease, S1: 97–105  
in terminal renal failure, prevention of, 202–210  
total protein excretion and, 418–426
- Alcohol dehydrogenase inhibitor, for diethylene glycol poisoning, 958–962
- Alcoholism prevalence, in dialysis patients, 1039–1043
- Allograft dysfunction  
in adult male, 997–1001  
vein thrombosis, surgical thrombectomy of, 5:E21
- Allograft failure, with systemic lupus erythematosus, 1242–1247
- Allograft nephropathy, angiotensin-converting enzyme inhibitors in, 154–156
- Allopurinol, for familial microscopic hematuria, 141–145
- Alternative medicine  
Chinese herbal nephropathy and, 330–331  
noni juice-induced hyperkalemia, 310–311
- Aminoguanidine, inhibition of AGEs, 373–374
- Amlodipine, for hypertensive ADPKD patients, 427–432
- Amyloidosis  
remission after Castleman's disease removal, 1207–1211  
secondary  
in fibrillary glomerulonephritis, 173–177  
in giant-cell arteritis, 137–140  
in polymyalgia rheumatica, 137–140
- ANCA (antineutrophil cytoplasmic antibody), in anti-GBM-associated glomerulonephritis, 954–957
- Anemia  
in ESRD  
iron therapy for, 1–12  
with sleep disorders, mortality prediction for, 1052–1061  
exacerbation in CRF, ACE inhibitors and, 1076–1082
- Angitis, MPO-ANCA-associated, 889–895
- Angiotensin, in renal fibrosis, maximal reduction of, 773–776
- Angiotensin-converting enzyme gene polymorphisms  
DD, RVD survival and, 211–215  
insertion/deletion, IgA nephropathy progression and, 896–903
- Angiotensin-converting enzyme inhibitors  
antiproteinuric effect, 381–391  
in chronic allograft nephropathy, 154–156  
in diabetic and nondiabetic chronic renal disease, 695–707  
for hypertensive ADPKD patients, 427–432  
kidney disease progression and, 1155–1165  
for prevention of terminal renal failure in albuminuria, 202–210  
for renal transplant recipients, 58–63  
rHuEPO requirements in hemodialysis and, 1076–1082
- Angiotensin II  
in immune-mediated renal injury, 166–172  
in progressive glomerulosclerosis, 179–188
- Angiotensin II antagonists  
for chronic allograft nephropathy, 154–156  
for renal transplant recipients, 58–63
- Angiotensin receptors, new research on, 5: i–iii
- Anion gap increase, in metabolic acidosis of hemodialysis, 1068–1072
- Anthropometry methods. *See also specific anthropometric methods*  
nutritional status in maintenance dialysis and, S2:32–33  
performance, S2:76–85
- Antibiotics, for chronic hemodialysis, 64–68
- Anticoagulation  
heparin vs. rTPA, for Quinton Permocath priming, 130–136  
population pharmacodynamic model for, 89–94  
regional citrate, in CVVHDF, 802–811
- Anti-glomerular basement membrane antibodies, glomerulonephritis-associated with, 954–957
- Anti-glomerular basement membrane disease  
glomerulonephritis, albumin processing in, 418–426  
pathogenesis, All and, 166–172
- Antihypertensive therapy  
for hypertensive ADPKD patients, 427–432  
for nondiabetic nephropathy, 4: liv–lvi
- Antineutrophil cytoplasmic antibody (ANCA), in anti-GBM-associated glomerulonephritis, 954–957
- Antioxidant, effects on PKD murine model, 221–226
- Antiphospholipid antibodies, vascular access thrombosis and, 796–801

- Anti-Thy1 nephritis, albumin processing in, 418–426  
 ANZDATA registry, cross-cultural comparison of renal disease classifications, 157–165  
 Arachnoid cysts, subdural hematoma in ADPKD and, 40–43  
 Area under concentration curve, for tacrolimus monitoring of transplant recipients, 660–666  
 ARF. *See* Acute renal failure  
 L-Arginine, effects on polycystic rat model, 930–936  
 Aristolochic acid, fibrosing interstitial nephritis from, 313–318  
 Arterial compliance, dialysate calcium level in hemodialysis and, 1096–1103  
 Arteriole calcification, in chronic renal failure, 588–597  
 Arteriopathic renal diseases, cross-cultural classification comparisons, 162  
 Arteriovenous fistula, microembolic signals in, 526–528  
 Arteriovenous graft, microembolic signals in, 526–528  
 AT1a receptor knockout, immune-mediated renal injury and, 166–172  
 Atherosclerotic renovascular disease (ARVD), epidemiology/clinical manifestations, 573–587  
 AT II antagonists. *See* Angiotensin II antagonists  
 Autosomal dominant polycystic kidney disease (ADPKD)  
   age of hemodialysis induction, gender differences in, 1072–1075  
   chronic subdural hematoma in, 40–43  
   ESRD, laparoscopic nephrectomy for, 720–725  
   hypertension, antihypertensive therapy for, 427–432  
   with Marfan syndrome in kindred, 753–760  
   pain management in, 770–772  
   progression, hypertension/proteinuria and, 547–550  
   racial variation in, 35–39  
   renal mass reduction for, 923–929  
 Azotemia  
   differential diagnosis, Doppler ultrasound for, 713–719  
   neutrophil  $\beta_2$ -microglobulin and lactoferrin content in, 1117–1126  
 Basic fibroblast growth factor, during peritonitis CAPD, 644–652  
 BCG (bromresol green assay), S2:66  
 Berger's disease, histologic features, survival and, 392–400  
 BIA (bioelectrical impedance analysis), S2:86  
 Bicarbonate, serum  
   low, treatment of, S2: 38–39  
   in maintenance dialysis  
     measurement, 39, S2: 38  
     pediatric guidelines, S2:107–108  
 Bicarbonate-buffered peritoneal dialysis fluid, ex vivo peritoneal macrophage function and, 112–121  
 Bicarbonate dialysate concentration, metabolic acidosis and, 1224–1225  
 Biocompatibility  
   of bicarbonate-buffered dialysis fluids, 112–121  
   of dialyzer membranes, outcome and, 980–991  
   of vitamin E-coated dialyzer membranes, 95–104  
 Bioelectrical impedance analysis (BIA), S2:86  
 Biological scaling, Kt/V and, 306–309  
 Blacks  
   ADPKD in, 35–39  
   blood pressure in hemodialysis, 257–265  
 idiopathic focal segmental glomerulosclerosis in, 878–883  
 mortality risk with dialysis dose, body size and, 80–88  
 Blood flow, in curved-tip vs. standard dialysis catheters, 624–628  
 Blood pressure  
   in chronic hemodialysis, 257–265  
     dialysate calcium level and, 1096–1103  
     seasonal variations, 812–818  
     and ultrafiltration, 819–826  
   circadian variation in rHuEPO therapy for CRF and, 250–256  
   normal, glomerular filtration rate and, 1144–1148  
   post-transplantation changes in children, 681–686  
   predictive accuracy for graft thrombosis, 1089–1095  
   in renal insufficiency, smoking-related progression of, 687–694  
   renal mass reduction, adaptation in polycystic rat, 923–929  
 Blood vessel prosthesis blood flow decrease, in graft thrombosis prediction, 1089–1095  
 Blood volume, in hemodialysis and ultrafiltration, 819–826  
 BMI. *See* Body mass index  
 Body fat, estimation, S2:81–82  
 Body mass index (BMI)  
   calculation, S2:77  
   glomerular filtration rate in normotension and, 1144–1148  
   hemodialysis dose, mortality and, 80–88  
   urea reduction ratio, urea product and, 598–605  
 Body size, hemodialysis dose, mortality and, 80–88  
 Body weight  
   excessive. *See* Obesity  
   glomerular filtration rate in normotension and, 1144–1148  
   interdialytic gain, blood pressure in hemodialysis and, 257–265  
   measurements  
     by age, S2:130–131  
     methods for, S2:124  
     standard, percentage of, S2:76–77  
     standing, measurement method, S2:124  
 Bone densitometry, of long-term renal transplant recipients, 227–236  
 Bone histomorphometry  
   of long-term renal transplant recipients, 227–236  
   22-oxacalcitriol effects on, 458–464  
 Bone loss, renal transplant-associated, 1,25-dihydroxyvitamin D<sub>3</sub> and calcium carbonate effects on, 227–236  
 Bovine thrombin antibodies, vascular access thrombosis and, 796–801  
 Bowman's capsule volume, digital reconstruction in glomerulocystic kidney disease, 216–220  
 Brachiocephalic vein occlusion, secondary unilateral breast enlargement from, E:26  
 Breast cancer screening, failure of, 327–329  
 Bromresol green assay (BCG), S2:66  
 Calcifications  
   in chronic renal failure, 588–597  
   peritoneal, after long-term CAPD, 761–766  
 Calciphylaxis, in chronic renal failure, 588–597

- Calcitriol, pulsed-dose, for secondary hyperparathyroidism, 465–468
- Calcium  
in dialysate, arterial compliance in hemodialysis and, 1096–1103  
posthemofiltration levels, for regional citrate anticoagulation, 802–811
- Calcium carbonate, renal transplant-associated bone loss and, 227–236
- Calcium channel blockers, for hypertensive ADPKD patients, 427–432
- Calcium oxalate, in familial microscopic hematuria urine sediment, 141–145
- Cancer  
dialysis-associated, incidence/spectrum of, 347–353  
screening  
breast, failure of, 327–329  
in end-stage renal disease, life expectancy benefits of, 237–243
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Cardiac compromise, improving hemodynamic stability during hemodialysis, 5:E19
- Cardiac oxygen supply/demand, in hemodialysis and ultrafiltration, 819–826
- Cardiac valve surgery, mild renal failure outcome after, 1127–1134
- Cardiopulmonary manifestations, of Henoch-Schönlein purpura, 319–322
- Cardiopulmonary vasculitis, in Henoch-Schönlein purpura, 319–322
- Cardiovascular disease  
chronic renal disease and, S1:117–131  
comorbidity, blood pressure in hemodialysis and, 259, 261, 262–263  
mortality prediction in hemodialysis, CRP and, 469–476  
risk  
proteinuria and, S1:97–105  
small dense LDL and, 852–862
- L-Carnitine, for maintenance dialysis  
adults, S2:54–55  
children, S2:88–92
- Case-control design study, of prolonged hypoglycemia in ESRD, 500–505
- Castleman's disease, localized removal, nephrotic syndrome remission after, 1207–1211
- Catheters  
hemodialysis  
blood flow in curved-tip vs. standard, 624–628  
central venous soft cuffed implantable, priming of, 130–136  
facility specific standardized ratio calculation, 275–281  
peritoneal dialysis  
pediatric, 1111–1116  
repositioning, Fogarty catheter manipulation for, 301–305
- C4d, antibody-mediated graft injury in spousal-donor kidney transplantation, 667–673
- CD4 lymphocytes, in renal disease in HIV-transgenic mice, 408–417
- Celecoxib, nephrotoxicity, 937–940
- Cell proliferation, in polycystic kidney disease, lovastatin and, 221–226
- Channel inducing factor (CHIF), in acute renal failure, 871–877
- Charcoal hemoperfusion, for phenytoin overdosage, 323–326
- Children  
acid-base status management guidelines, S2:107–108  
diethylene glycol poisoning in, 958–962  
with hemolytic uremic syndrome, TGF $\beta$ -1 and lymphokines in, 29–34  
hypertensive emergencies, nicardipine for, 5:E20  
kidney transplantation, abnormal 24-hour blood pressure patterns, 681–686
- maintenance dialysis. *See* K/KOQI Nutrition Clinical Practice Guidelines, pediatric
- peritoneal dialysis, catheter choice for, 1111–1116
- renal effects of cocaine exposure, 783–795
- Chinese herb nephropathy (CHN)  
incidence of, 330–331  
progressive fibrosing interstitial nephritis in, 313–318
- Cholesterol  
nutritional status in maintenance dialysis and, S2:25–26  
in PKD model, probucol effects on, 221–226
- Chronic interstitial nephritis, incidence, 878–883
- Chronic renal failure, progression in hypertension, augmentation by smoking, 687–694
- Chronic renal failure (CRF). *See also* End-stage renal disease  
ADPKD-associated, racial variation in, 35–39  
anemia exacerbation, ACE inhibitors and, 1076–1082  
calcified arterioles and subcutaneous infarcts in, 588–597  
cocaine in, 790–791  
delayed by ACE inhibition, 202–210
- Dialysis Outcomes Quality Initiative, S1:69–75
- EPO therapy, hematocrit target for, 250–256
- hemodialysis, diabetic muscle infarction and, 1212–1216
- in juvenile nephronophthisis, 44–51
- nondialyzed  
dietary energy intake for, S2:60–61  
dietary protein intake for, S2:58–59  
intensive nutritional counseling for, S2:62–63  
nutritional measures for, S2:56–57
- prediction, in IgA nephropathy, 13–20
- progression, aminoguanidine prevention of, 365–380
- protein-energy malnutrition causes, S2:9
- proteinuria and, S1:97–105
- renal biopsy, 448–457
- survival after acute myocardial infarction, 1044–1051
- ultrasonography, 1021–1039
- Cigarette smoking. *See* Smoking
- Circadian rhythm, blood pressure variation, rHuEPO therapy for CRF and, 250–256
- Citrate anticoagulation, regional, in CVVHDF, 802–811
- Citrate dialysis, dialysis dose and, 493–499
- Classification  
of Haas, prognostic value of, 13–20  
of primary renal diseases, world-wide differences in, 157–165
- Clinical performance measures, Dialysis Outcomes Quality Initiative, S1:69–75

- Clinical practice guidelines, Dialysis Outcomes Quality Initiative, S1:69–75
- Coagulation. *See also* Anticoagulation  
in crescentic glomerulonephritis, 726–738
- Cocaine abuse, kidney and, 783–795
- Cohort study, of survival after myocardial infarction in ESRD, 1044–1051
- Comorbidity  
in hemodialysis, 2:xlvii–xlviii  
reuse-associate mortality and, 244–249
- Complement activation, in Henoch-Schönlein purpura nephritis, 401–407
- Complement C3, in IgA nephropathy, 21–28
- Complex traits, in kidney disease, S1:160–169
- Compliance. *See also* Noncompliance  
alcoholism and, 1039–1043  
blood pressure and, 257–265  
with dialysis exchanges in peritoneal dialysis, 1104–1110
- Congenital diseases, cross-cultural classification comparisons, 157–165
- Congestive heart failure  
atherosclerotic renovascular disease and, 573–587  
comorbidity, blood pressure in hemodialysis and, 257–265
- Continuous ambulatory peritoneal dialysis (CAPD)  
catheter migration, Fogarty catheter manipulation for, 301–305  
long-term, ectopic intestinal wall calcification in, 761–766  
noncompliance, in US vs. Canada, 506–514  
noncompliance pattern with dialysis exchanges, 1104–1110  
for peritonitis, cytokine profile changes in, 644–652  
sexual dysfunction after, 845–851
- Continuous venovenous hemodiafiltration (CVVHDF), regional citrate anticoagulation in, 802–811
- Cook catheters, for pediatric peritoneal dialysis, 1111–1116
- Coronary artery disease, risk, with hyperphosphatemia and hyperparathyroidism in dialysis, 1226–1237
- Corticosteroids, for diffuse proliferative IgA nephropathy, 194–201
- Cox2 selective inhibitors, nephrotoxicity, 976–977
- C1q nephropathy, spontaneous improvement, 5:E22
- C-reactive protein (CRP)  
in IgA nephropathy, 21–28  
mortality prediction in hemodialysis and, 469–476
- Creatinine  
in hypertensive-associated renal disease, smoking and, 687–694  
mild renal failure outcome after cardiac valve surgery and, 1127–1134  
nutritional status in maintenance dialysis and, S2:23–24
- Creatinine clearance  
in Japanese peritoneal dialysis patients, 515–525  
long-term cyclosporine monotherapy in transplant patients and, 1135–1143  
in overweight normotensive humans, 1144–1148
- Creatinine index  
calculation, S2:67  
nutritional status in maintenance dialysis and, S2:23–24  
usage, S2:67
- Creatinine urine/serum ratio, in differentiation of prerenal azotemia from ATN, 713–719
- Crescentic glomerulonephritis, tissue factor, PAI-1 and thrombin receptor expression in, 726–738
- Crescents  
IgA nephropathy prognosis and, 13–20  
in pauci-immune necrotizing lupus nephritis, 1193–1206
- Cross-cultural comparison, of primary renal disease classifications, 157–165
- Cross-infection in chronic hemodialysis, risk factors for, 1083–1089
- CRP. *See* C-reactive protein
- Cryoglobulinemia glomerulopathy, splenectomy and, 1186–1192
- Cuprammonium membrane biocompatibility, serum albumin and, 606–610
- CVVHDF (continuous venovenous hemodiafiltration), regional citrate anticoagulation in, 802–811
- Cyclooxygenase-2, renal cell adaptation to hypertonicity and, 6:xlvii–1
- Cyclooxygenase-2 enzyme inhibitors, nephrotoxicity, 937–940
- Cyclophosphamide, long-term, for post-transplant MPGN prophylaxis, 539–542
- Cyclosporine  
long-term, for post-transplant MPGN prophylaxis, 539–542  
nephrotoxicity of, 333–346  
for transplant patients, long-term results of, 1135–1143
- Cryoglobulinemia, subclinical, in HD and KT patients, 52–57
- Cytokines. *See also* specific cytokines  
induction  
through dialyzer membranes, in ESRD, 611–616  
vitamin E-coated dialyzer membranes and, 95–104  
profile changes during peritonitis CAPD, 644–652
- 1,25(OH)D<sub>3</sub> derivatives, for secondary hyperparathyroidism in CAPD, 761–766
- DEG (diethylene glycol), childhood poisoning, treatment of, 958–962
- Depression, in end-stage renal disease, S1:132–140
- Dextran fractional clearance, ACE inhibition and, 381–391
- Diabetes mellitus  
chronic renal disease, ACEi effects in, 695–707  
complications. *See also* Diabetic nephropathy  
advanced glycation end products and, 369–370  
muscle infarction in dialysis patients, 1212–1216  
cross-cultural classification comparisons, 157–165  
end-stage renal disease, prolonged sulfonylurea-induced hypoglycemia in, 500–505  
hemodialysis, septicemia in, 282–292  
with proteinuria, cardiovascular morbidity/mortality and, S1:97–105  
type 2  
familial clustering of proteinuria in, 708–712  
progressive renal failure with nephrotic syndrome in, 173–177
- Diabetic nephropathy  
gender differences, vs. ADPKD, 1072–1075  
incidence, 878–883

- pancreatic transplant for, 1238–1241  
progression and response to treatment, 1155–1165
- Dialysate  
bicarbonate concentration, metabolic acidosis and, 1224–1225  
calcium, effect on arterial compliance, 1096–1103  
citrate vs. acetic, dialysis dose and, 493–499  
in vivo flow rate, Kt/V maintenance and, 105–111
- Dialysis. *See* Hemodialysis; Peritoneal dialysis
- Dialysis cannulas, curved-tip vs. standard, 624–628
- Dialysis dose  
citrate vs. acetic dialysate and, 493–499  
Kt/V and, 306–309  
mortality risk, body size and, 80–88  
multicenter cross-sectional study, 515–525  
in vivo effects of dialysate flow rate on, 105–111
- Dialysis health care team, demands of functionally dependent patients on, 1061–1067
- Dialysis Outcomes Quality Initiative (DOQI), history, impact and prospects, S1:69–75
- Dialyzer membranes  
biocompatibility  
in intermittent hemodialysis, outcome and, 980–991  
serum albumin and, 606–610  
low-flux, permeability of, 839–844  
polysulfone, serum albumin levels and, 606–610  
vitamin E-coated, T-cell activation, cytokine induction and, 95–104
- Dialyzer reuse  
mortality, disease severity, hematocrit and, 244–249  
permeability of low-flux membranes and, 839–844  
population pharmacodynamic model for heparin dosing and, 89–94  
septicemia in diabetics vs. nondiabetics and, 282–292
- Dialyzers  
double, URR and Kt/V improvement with, 266–274  
reuse. *See* Dialyzer reuse
- Dietary interviews/diaries  
nutritional status in maintenance dialysis and, S2:27  
protein intake expression/calculation, S2:68–69  
validity/reliability, S2:68
- Dietary protein intake  
in chronic peritoneal dialysis, S2: 42–43  
in maintenance hemodialysis, S2: 40–41
- Diethylene glycol (DEG), childhood poisoning, treatment of, 958–962
- 1,25-Dihydroxyvitamin D<sub>3</sub>, renal transplant-associated bone loss and, 227–236
- Disease severity, dialyzer reuse-associated mortality and, 244–249
- Distal tubule acidification, physiologic/pathophysiologic consequences, 3: lii–liv
- Diurnal rhythm, of blood pressure, left ventricular hypertrophy risk in hemodialysis and, 617–623
- Doppler ultrasound  
acute renal failure diagnosis, 713–719  
continuous-wave, for vascular access monitoring, 477–481
- DOQI (Dialysis Outcomes Quality Initiative), history, impact and prospects, S1:69–75
- Dual energy X-ray absorptiometry (DXA), nutritional status in maintenance dialysis and, S2:34–35
- Duplex ultrasound, detection of microembolic signals in HD access, 526–528
- EDTA registry, cross-cultural comparison of renal disease classifications, 157–165
- Elderly  
acute renal insufficiency in, 433–447  
renal biopsy in, 544–546
- Electrolyte imbalance, cocaine-induced, 789
- Emotional distress, from renal replacement therapies, comparison of, 629–637
- Enalapril, for hypertensive ADPKD patients, 427–432
- Endocapillary proliferative glomerulonephritis, parvovirus B19 infection after, 6:E31
- Endothelial injury, AII and PAI-1 in, 179–188
- Endothelin secretion, H<sup>+</sup>-stimulated, physiologic/pathophysiological consequences, 3: lii–liv
- End-stage renal disease (ESRD)  
ADPKD-associated  
laparoscopic nephrectomy for, 720–725  
racial variation in, 35–39  
alcoholism and, 1039–1043  
anemia  
exacerbation, ACE inhibitors and, 1076–1082  
parenteral iron use for, 1–12  
atherogenic lipoprotein phenotype in, 852–862  
cancer screening, life expectancy benefits of, 237–243  
chronic hemodialysis  
demands on health care team, 1061–1067  
metabolic acidosis in, 1069–1072  
diabetic, prolonged sulfonylurea-induced hypoglycemia in, 500–505  
DOQI and, S1:69–75  
hemodialysis  
iron therapy and, 1–12  
for normeperidine-induced neurotoxicity, 146–149  
with sleep disorders, mortality predictors for, 1052–1061  
sleep disorders and, 1221–1223  
with hypertension, smoking-related progression of, 687–694  
IGF-1 after peritoneal dialysis, renal function improvement from, 150–153  
immobilization, hypercalcemia from, 969–972  
lead-induced, in dialysis patient, 963–968  
from lupus nephritis  
outcome predictors for, 904–914  
renal transplant access for, 915–922
- Medicare program  
1971 amendment and, S1:45–48  
historical aspects of, S1:37–44
- outcome  
predictors of, 69–79  
URR vs. urea product and, 598–605  
psychosocial factors, S1:132–140  
renal rehabilitation and, S1:141–147  
severity, dialyzer reuse-associated mortality and, 244–249  
with sleep disorders, mortality predictors for, 1052–1061  
survival  
ACE gene polymorphism and, 211–215  
after myocardial infarction and, 1044–1051

- T-cell activation in, hemodialysis initiation and, 611–616  
treatment, future developments in, S1:106–116  
world-wide classification differences in, 157–165
- Energy intake**  
expression/calculation, from dietary interviews/diaries, S2: 68–69  
maintenance dialysis  
during acute illness, S2:51–53  
adult, S2:44–45  
pediatric, S2:112–113  
for nondialyzed CRF, S2:60–61
- Enterococcus infection**, in chronic hemodialysis patients, vancomycin for, 64–68
- EPO.** *See* Erythropoietin
- Erythropoietin (EPO)**  
and iron therapy, for ESRD anemia, 1–12  
recombinant human  
hematocrit target for, 250–256  
resistance in hemodialysis, ACE inhibitors and, 1076–1082
- Escherichia coli**, Shiga-like toxin-producing. *See* Verotoxin-producing *Escherichia coli*
- ESRD.** *See* End-stage renal disease
- Ethical issues**  
of kidney vending, 1002–1018  
of renal transplantation, S1:153–159
- Exercise**, by hemodialysis patients, self-reports on, 482–492
- Familial clustering**  
of ADPKD-associated ESRD, 35–39  
cross-cultural classification comparisons, 157–165  
of proteinuria in type 2 diabetes, 708–712
- Familial microscopic hematuria**, with hypercalciuria and/or hyperuricosuria, 141–145
- Fanconi syndrome**, with urinary free kappa light chains, 777–781
- FBN1 locus**, ADPKD with Marfan syndrome in kindred, 753–760
- Ferrlecit**, for end-stage renal disease anemia, 1–12
- Fibrillary deposits**, renal biopsy, differential diagnosis of, 173–177
- Fibrillary glomerulonephritis (FGN)**, differential diagnosis, 173–177
- Fibrils**, differential diagnosis in renal failure with diabetes, 173–177
- Fibrinolysis**, in crescentic glomerulonephritis, 726–738
- Fibrosing interstitial nephritis**, Chinese herbal drugs and, 313–318
- Fistula**  
facility specific standardized ratio calculation, 275–281  
microembolic signals in, 526–528
- FK506.** *See* Tacrolimus
- Flow cytometry cross-matching**, detection of antibody-mediated allograft rejection, 667–673
- Fluorescent dye technique**, for urinary albumin detection, 739–744
- Focal segmental glomerulonephritis**, HIV-associated, T lymphocytes in, 408–417
- Focal segmental glomerulosclerosis (FSGS)**  
idiopathic, increasing incidence of, 878–883  
kidney tissue, parvovirus B19DNA in, 1166–1174
- Fogarty catheter**, manipulation for PD catheter repositioning, 301–305
- Fomepizole**, for diethylene glycol poisoning in child, 958–962
- Fractional clearance index for urea**, improvement with two parallel dialyzers, 266–274
- Fractional clearance of dextran**, ACE inhibition and, 381–391
- Fractional excretion of sodium**, in differentiation of prerenal azotemia from ATN, 713–719
- Free kappa light chains**, in Fanconi syndrome urine, 777–781
- Gender differences**  
in L-NAME effects on polycystic rat model, 930–936  
in mean age for ADPKD hemodialysis induction, 1072–1075  
in sexual dysfunction after renal replacement therapy, 845–851
- Gene polymorphism**, IgA nephropathy progression and, 896–903
- Gene therapy**, for kidney disease, S1:160–169
- Genetics**, of kidney disease, S1:160–167
- Genitourinary embryogenesis**, cocaine effects on, 783–795
- Germicide**, reuse-associated mortality and, 244–249
- GFR.** *See* Glomerular filtration rate
- Giant-cell arteritis**, secondary amyloidosis in, 137–140
- Glomerular basement membrane**, autoantibodies, in ESRD, 954–957
- Glomerular chemiluminescence**, of reactive oxygen species in puromycin aminonucleoside nephrosis, 1175–1185
- Glomerular filtration rate (GFR)**  
body scaling and, 306–309  
estimation, S2:87  
in overweight normotensive humans, 1144–1148
- Glomerulocytic kidney disease**, sporadic adult, digital reconstruction in, 216–220
- Glomerulonephritis**  
anti-GBM-associated, with pulmonary hemorrhage, 954–957  
chronic incidence, 878–883  
cross-cultural classification comparisons, 162–163  
in elderly with acute renal insufficiency, 433–447  
gender differences vs. ADPKD, 1072–1075  
in heme oxygenase-1 deficiency, 863–870  
IgE deposits in, 941–949  
parvovirus B19 infection after, 6:E31  
prognosis, histologic classification for, 13–20  
with thrombotic microangiopathy, in SLE and lupus-like syndrome, 1193–1206
- Glomerulonephrosis**, postinfectious, 1:xlvii–xlviii
- Glomerulopathy**  
transplant, in late graft loss, 674–680  
of type II mixed cryoglobulinemia, splenectomy and, 1186–1192  
ultrasonography, 1021–1039
- Glomerulosclerosis**  
development delay, ACE inhibition and, 202–210  
focal segmental. *See* Focal segmental glomerulosclerosis progressive, AII and PAI-1 in, 179–188

- Goodpasture's syndrome, autoantibody development in, 954–957
- Graft
- blood flow decrease, accuracy in graft thrombosis prediction, 1089–1095
  - facility specific standardized ratio, calculation of, 275–281
  - failure, with systemic lupus erythematosus, 1242–1247
  - loss, transplant glomerulopathy in, 674–680
  - microembolic signals in, 526–528
  - rejection vs. immunosuppressive drug nephrotoxicity, 333–346
  - survival, long-term cyclosporine monotherapy and, 1135–1143
  - thrombosis prediction, 973–975
- Growth measurements
- interval, for pediatric maintenance dialysis, S2:111
  - parameters for
    - evaluation, S2:125–132
    - methods, S2:124–125
- Han-SPRD rat polycystic kidney disease, L-NAME effects on, 930–936
- Haptoglobin, in heme oxygenase-1 deficiency, 863–870
- HCV. *See* Hepatitis C virus
- HD. *See* Hemodialysis
- Head circumference, measurement method, S2:124–125
- Health care costs, immunosuppressant-induced nephrotoxicity and, 341–342
- Health-related quality of life, renal rehabilitation and, S1:141–147
- Health status outcome. *See* Outcome
- Heat shock proteins (HSPs), renal cell adaptation to hypertonicity and, 6:xvii–I
- Heavy chain IgG<sub>2</sub> deposition disease, recurrence in renal transplant, 5:E25
- Height measurement
- by age, S2:128–129
  - method, S2:124
- Hematocrit
- dialyzer reuse-associated mortality and, 244–249
  - mortality prediction, for ESRD with sleep disorders, 1052–1061
  - target, for erythropoietin therapy, 250–256
- Hematuria
- IgA nephropathy prognosis and, 13–20
  - renal biopsy for, 448–457
  - with *Staphylococcus aureus* pneumonia, 354–359
  - with thin basement membrane disease and acute renal failure, 533–536
- Heme oxygenase-1 deficiency, tubulointerstitial injury in, 863–870
- Hemodialysis (HD)
- access. *See* Vascular access
  - age of induction, gender differences in ADPKD, 1072–1075
  - alcoholism prevalence and, 1039–1043
  - for anti-GBM-associated glomerulonephritis, 954–957
  - antiphospholipid antibodies, vascular access thrombosis and, 796–801
- arterial compliance in, dialysate calcium levels and, 1096–1103
- bone loss, with secondary hyperparathyroidism, 458–464
- cannulas, curved-tip vs. standard, 624–628
- cardiac-compromised patients, improving hemodynamic stability for, 5:E19
- cardiac/hemodynamic effects, 819–826
- catheters. *See* Catheters, hemodialysis
- of child, with diethylene glycol poisoning, 958–962
- chronic
- blood pressure factors in, 257–265
  - demands on health care team, 1061–1067
  - heparin model for improving dialyzer reuse rates, 89–94
  - hospital-acquired infections in, 1083–1089
  - metabolic acidosis in, 1069–1072
  - predictors of poor outcome in, 69–79
  - seasonal variations in BP and overhydration, 812–818
  - vancomycin for, 64–68
- for chronic renal disease, with cardiovascular disease, S1:117–131
- for cor triatriatum, left atrial calcification and, 5:E27
- diabetic muscle infarction, 1212–1216
- dose. *See* Dialysis dose
- with double dialyzers, URR and Kt/V improvement in, 266–274
- ESRD
- in future, S1:106–116
  - psychosocial factors in, S1:132–140
- health related quality-of-life changes after, 482–492
- hepatitis C virus in. *See* Hepatitis C virus, in hemodialysis initiation, T-cell activation in ESRD and, 611–616
- intermittent, impact on ARF outcome variables, 980–991
- iron therapy, parenteral, 1–12
- lead-induced peripheral neuropathy in, 963–968
- left ventricular hypertrophy, blood pressure variability and, 617–623
- maintenance. *See* Maintenance dialysis
- mortality, reuse-associated, HCT and disease severity and, 244–249
- for normeperidine-induced neurotoxicity, 146–149
- Ochrobactrum anthropi* bacteremia and, 6:E30
- outcome. *See* Outcome
- pruritus, ondansetron for, 821–831
- quality of life evaluation, vs. peritoneal dialysis, 293–300
- rHuEPO requirements, ACE inhibitors and, 1076–1082
- risks, with hyperphosphatemia and hyperparathyroidism, 1226–1237
- septicemia, in diabetic vs. nondiabetic patients, 282–292
- sexual dysfunction after, 845–851
- social factors, 2:xvi–xviii
- subclinical cryoglobulinemia in, 52–57
- technological improvements, 2:xvi–xviii
- Hemodynamics of hemodialysis
- dialysate calcium levels and, 1096–1103
  - and ultrafiltration, 819–826
- Hemolysis, in heme oxygenase-1 deficiency, 863–870
- Hemolytic uremic syndrome, circulating levels of TGF $\beta$ 1 and lymphokines in, 29–34
- Hemorrhage, regional citrate anticoagulation in CVVHDF and, 802–811
- Henoch-Schönlein purpura

- cardiopulmonary manifestations, 319–322  
nephritis, complement activation in, 401–407
- Heparin  
dosing, population pharmacodynamic model for, 89–94  
vs. rTPA, for Quinton Permethyl priming, 130–136
- Hepatitis C virus (HCV)  
cryoglobulinemia-associated, splenectomy for, 1186–1192  
in hemodialysis  
genotype assessment, 832–838  
RIBA serotyping SIA for, 832–838  
serotyping strip immunoblot assay for, 832–838  
subclinical cryoglobulinemia and, 52–57  
viral load, biological dynamics of, 122–129
- Herbal medicine  
Chinese, progressive fibrosing interstitial nephritis associated with, 313–318  
nephropathy and, 330–331  
noni juice-induced hyperkalemia, 310–311
- Heredity renal diseases, cross-cultural classification comparisons, 157–165
- Hispanics, idiopathic focal segmental glomerulosclerosis in, 878–883
- Histological classification  
IgA nephropathy outcome and, 392–400  
prognostic value, 13–20
- HIV infection. *See* Human immunodeficiency virus infection
- Home visits for peritoneal dialysis, noncompliance pattern with dialysis exchanges, 1104–1110
- Hospital-acquired infections, in chronic hemodialysis, risk factors for, 1083–1089
- Hospitalized patients, on chronic hemodialysis, vancomycin for, 64–68
- HSPs (heat shock proteins), renal cell adaptation to hypertonicity and, 6:xlvii–l
- H+–stimulated endothelin secretion, physiologic/pathophysiologic consequences, 3: iii–liv
- Human immunodeficiency virus infection  
HIVAN prevalence, 884–888  
nephropathy prevalence, 884–888  
renal mucormycosis, 5:E24  
with renal mucormycosis, 5:E24  
transgenic mice renal disease, T lymphocyte in, 408–417
- Human parvovirus. *See* Parvovirus B19
- Humoral rejection, as antirejection therapy target, 667–673
- Hydration state, seasonal variations in chronic hemodialysis, 812–818
- Hypercalcemia, from immobilization in ESRD, 969–972
- Hypercalciuria, in familial microscopic hematuria, 141–145
- Hyperkalemia  
noni juice ingestion, 310–311  
star fruit ingestion, 189–193
- Hyperparathyroidism  
risk in dialysis, 1226–1237  
secondary  
in CAPD, vitamin D<sub>3</sub> and calcium carbonate for, 761–766  
22-oxacalcitriol effect on bone histology in, 458–464  
pulsed-dose calcitriol for, 465–468
- Hyperphosphatemia, risk in dialysis, 1226–1237
- Hypertension  
in adaptation to renal mass reduction in polycystic rat, 923–929
- in ADPKD  
antihypertensive therapy for, 427–432  
with proteinuria, progression and, 547–550  
with chronic proteinuric nephropathy, ACE inhibitor for, 1155–1165
- cross-cultural classification comparisons, 162  
essential, renal insufficiency in, smoking and, 687–694
- IgA nephropathy prognosis and, 13–20  
pediatric emergencies, nicardipine for, 5:E20
- post-transplantation, in children, 681–686
- primary, smoking effects on outcome in, 767–769
- with progressive albuminuria, ACE inhibition for, 202–210
- renovascular, in atherosclerotic renovascular disease, 573–587
- as risk in hemodialysis with left ventricular hypertrophy, 617–623
- with *Staphylococcus aureus* pneumonia, 354–359
- Hypertensive nephrosclerosis, incidence, 878–883
- Hyperuricosuria, in familial microscopic hematuria, 141–145
- Hypoalbuminemia, mortality predictions, CRP and, 469–476
- Hypoglycemia, sulfonylurea-induced, in diabetics with ESRD, 500–505
- Hyponatremia, with *Staphylococcus aureus* pneumonia, 354–359
- IgA1 glycosylation, IgA nephropathy pathogenesis and, 551–556
- IgA nephropathy. *See* Immunoglobulin A nephropathy
- IGF-1 (insulin-like growth factor 1), after PD, renal function improvement from, 150–153
- Immobilization hypercalcemia, in end-stage renal disease, 969–972
- Immune function  
defect in ESRD, hemodialysis initiation effect on, 611–616  
vitamin E-coated dialyzer membranes and, 95–104
- Immunoabsorption, with staphylococcal protein A, for antibody-mediated allograft rejection, 667–673
- Immunoglobulin A (IgA)  
nephropathy. *See* Immunoglobulin A nephropathy  
subendothelial topography, in renal failure prediction, 13–20
- Immunoglobulin A nephropathy  
acute phase response and C3 activation in, 21–28  
diffuse proliferative, corticosteroids for, 194–201  
in Henoch-Schönlein purpura, 319–322  
incidence, 878–883  
outcome, histological grading system and, 392–400  
pathogenesis, IgA1 glycosylation and, 551–556  
prognosis, tubular grading and, 13–20  
progression, ACE gene insertion/deletion polymorphism in, 896–903
- Immunoglobulin E deposits, with renal tubular acidosis and vasculitis, 941–949
- Immunosuppressive drugs

- for anti-GBM-associated glomerulonephritis, 954–957  
for Henoch-Schönlein purpura, 319–322  
history in renal transplantation, S1:153–159  
nephrotoxicity, 333–346  
**Immunotactoid glomerulopathy**, differential diagnosis, 173–177  
Infants, renal effects of cocaine exposure, 783–795  
**Infections**  
nosocomial, in chronic hemodialysis, 1083–1089  
septicemia, in diabetic *vs.* nondiabetic hemodialysis patients, 282–292  
Inflammation, hypoalbuminemia effect on hemodialysis mortality and, 469–476  
Inherited disorders, of kidney, S1:160–169  
**In situ hybridization**, detection of parvovirus B19DNA in FSGS kidney tissue, 1166–1174  
Insulin clearance, in ESRD treated with IGF1 and PD, 150–153  
Insulin-like growth factor 1 (IGF-1), after PD, renal function improvement from, 150–153  
Intensity, of intermittent hemodialysis, outcome and, 980–991  
**Interferon- $\gamma$**  circulating levels, in hemolytic uremic syndrome, 29–34  
**Interleukins**  
circulating levels, in hemolytic uremic syndrome, 29–34  
during peritonitis CAPD, 644–652  
**Interstitial nephritis**  
in AIDS, with acute renal failure, 557–561  
in elderly with acute renal insufficiency, 433–447  
**Intrarenal arteries**, in Takayasu's arteritis, 950–953  
Iron dextran, for end-stage renal disease anemia, 1–12  
Iron gluconate, for end-stage renal disease anemia, 1–12  
Iron sucrose (iron saccharate), for end-stage renal disease anemia, 1–12  
**Ischemia-reperfusion**, potassium handling in ARF and, 871–877  
**Japanese population**  
with IgA nephropathy, ACE gene insertion/deletion polymorphism in, 896–903  
MPO-ANCA-associated angitis/nephritis in, 889–895  
**Juvenile nephronophthisis**, clinical/molecular heterogeneity of, 44–51  
**KEEP (Kidney Early Evaluation Program)**, S1:78  
**Kidney**  
cocaine abuse and, 783–795  
function  
long-term immunosuppressive drug therapy and, 333–346  
monitoring, 338  
transplanted, renal biopsy for, 448–457  
vending, ethical issues, 1002–1018  
**Kidney disease**. *See also specific kidney diseases*  
chronic  
cardiovascular disease and, S1:117–131  
risk factor reduction, to prevent CVD, S1:117–131  
genetics, S1:160–167  
progression, with ACE inhibitor treatment, 1155–1165  
ultrasonography, 1021–1039  
world-wide classification differences in, 157–165  
**K/DOQI Nutrition Clinical Practice Guidelines**  
adult  
acid-base status management, S2:38–39  
nutritional measures, S2:17–37  
protein/energy intake management, S2:40–41  
definition, S2:11  
development  
abstraction, S2:13  
article selection, critical appraisal methods for, S2:13–14  
draft report, S2:15  
formulation, S2:14–15  
literature review, S2:12–13  
peer review, S2:15  
targeting/focus for, S2:12  
work group member selection, S2:11–12  
evidentiary basis for, S2:11–15  
final, issuance of, S2:11  
guiding principles, S2:11  
implementation planning, S2:15–16  
pediatric  
acid-base status management, S2:107–108  
energy intake, S2:112–113  
interval measurements, S2:111  
mineral requirements, S2:116–117  
nutritional status assessment, S2:105–106  
nutritional supplementation, S2:120–121  
nutrition management, S2:118–119  
protein intake, S2:114–115  
urea kinetic modeling, S2:109–110  
vitamin requirements, S2:116–117  
for PEM prevention/treatment, S2:9–10  
Knockout mice, AT1a, immune-mediated renal injury and, 166–172  
**Kt/V**  
biological scaling and, 306–309  
of citric acid dialysate, 493–499  
equilibrated, mortality risk, body size and, 80–88  
in Japanese peritoneal dialysis patients, 515–525  
as outcome-based measure of hemodialysis dose, 598–605  
protein catabolic rate, dialyzer membrane change and, 606–610  
in vivo dialysate flow rate effects on, 105–111  
**Lactate-buffered peritoneal dialysis fluid**, ex vivo peritoneal macrophage function and, 112–121  
**Lactoferrin**, in PMNLs of renal failure patients, 1117–1126  
**Laparoscopic nephrectomy**, for ESRD in ADPKD, 720–725  
**Lead-induced peripheral neuropathy**, in dialysis patient, 963–968  
**Lectin pathway**, for complement activation in HSPN, 401–407  
**Left atrial calcification**, in hemodialysis patient with cor triatriatum, 5:E27  
**Left ventricular hypertrophy**  
in chronic renal failure, rHuEPO therapy for, 250–256  
risk in hemodialysis, blood pressure variability and, 617–623  
**Length measurements**, for infants, S2:132

- Life span**  
 cancer screening in end-stage renal disease and, 237–243  
 observed/expected, for ESRD, 653–659
- Liver cirrhosis**, with HCV-related cryoglobulinemia, splenectomy for, 1186–1192
- Losartan**, for kidney transplant recipients, 58–63
- Lovastatin**, effect in murine polycystic kidney disease model, 221–226
- Low-density lipoprotein (LDL)**, small dense, 852–862
- Lupus nephritis**  
 ESRD, renal transplant access for, 915–922  
 outcome predictors, 904–914  
 pauci-immune, with thrombotic microangiopathy, 1193–1206  
 remission, predictive features in, 904–914
- Lymphokines**. *See also specific lymphokines*  
 circulating levels, in hemolytic uremic syndrome, 29–34  
 $T_{H}2$ -associated. *See* Interleukins
- MAC**. *See* Mid-arm circumference
- Macrophages**  
 cytokine profile changes during peritonitis in CAPD patients, 644–652  
 in renal disease of HIV-transgenic mice, 408–417  
 in vivo function, bicarbonate/lactate vs. bicarbonate buffered PDF, 112–121
- Magnetic resonance angiography (MRA)**, of access recirculation in native fistula, 529–532
- Magnetic resonance imaging (MRI)**  
 acute bilateral renal cortical necrosis, 745–748  
 diabetic muscle infarction, 1212–1216
- Maintenance dialysis**  
 acid-base status management, pediatric guidelines, S2:107–108  
 biological dynamics of HCV viral load in, 122–129  
 L-carnitine  
   adult, S2:54–55  
   children, S2:88–92  
 dietary protein intake, S2: 40–41  
 energy intake, S2: 44–45  
 nutritional counseling, intensive, S2:46–47  
 nutritional measures, S2:17–19  
   adjusted edema-free body weight, S2:36–37  
   anthropometry, S2:32–33  
   cholesterol, S2:25–26  
   creatinine, serum, S2:23–24  
   creatinine index, S2:23–24  
   dietary interviews/diaries, S2:27  
   DXA, S2:34–35  
   PNA, S2:28–29  
   serum albumin, S2:20–21  
   serum prealbumin, S2:22  
   SGA, S2:30–31  
 nutritional support indications, S2:48–50  
 pediatric  
   mineral requirements, S2:116–117  
   nutritional supplementation, S2:120–121  
   nutrition counseling, S2:118–119  
   protein intake, S2:114–115  
   urea kinetic modeling, S2:109–110  
   vitamin requirements, S2:116–117  
 Qd effect on Kt/V, 105–111
- Malaria**, post-transplant thrombocytopenia and, 537–538
- MAMA** (mid-arm muscle area), calculation, S2:125–127
- MAMC**. *See* Mid-arm muscle circumference
- Manose-binding lectin**, for complement activation in HSPN, 401–407
- Marfan syndrome**, with ADPKD in kindred, 753–760
- MCN** (minimal change nephropathy), incidence, 878–883
- MCP-1** (monocyte chemoattractant protein-1), AI and, 166–172
- Mean arterial pressure**. *See* Blood pressure
- Medical Outcomes Study Short Form 36-item questionnaire**.  
*See* Short Form 36-item questionnaire
- Membranoproliferative glomerulonephritis (MPGN)**  
 incidence, 878–883
- post-transplant**  
 cyclophosphamide prophylaxis for, 539–542  
 plasmapheresis for, 749–752
- Membranous nephropathy (MN)**  
 idiopathic, ACE inhibition in, 381–391  
 incidence, 878–883
- Men**. *See* Gender differences
- Meperidine metabolite**. *See* Normeperidine
- Mesangial phenotypic modulation**, in IgA nephropathy, early corticosteroids for, 194–201
- Mesangiolysis**, in glomerulonephritis after parvovirus B19 infection, 6:E31
- Mesothelial cells**, cytokine profiles, during peritonitis, 644–652
- Meta-analysis**  
 ACE inhibition in diabetic vs. nondiabetic chronic renal disease, 695–707  
 quality of life from renal replacement therapies, 629–637
- Metabolic acidosis**  
 correction, pediatric guidelines, S2:107–108  
 dialysate bicarbonate concentration and, 1224–1225  
 in hemodialysis patients, 1068–1072  
 treatment, S2: 39
- $\beta_2$ -Microglobulin**  
 in PMNLs of renal failure patients, 1117–1126  
 in ultrafiltrate, for assessment of low-flux membrane permeability, 839–844
- Mid-arm circumference (MAC)**  
 adult, S2:82–84  
 pediatric, S2:125
- Mid-arm muscle area (MAMA)**, calculation, S2:125–127
- Mid-arm muscle circumference (MAMC)**  
 adult, S2:82–85  
 pediatric, S2:125–126
- Mineral requirements**, pediatric maintenance dialysis, S2: 116–117
- Minimal change nephropathy (MCN)**, incidence, 878–883
- Mitogen-activating protein kinases (MAP kinases)**, renal cell adaptation to hypertonicity and, 6:xlvi–l
- Modeling**, population pharmacodynamic, for heparin dosing and, 89–94
- Monocyte chemoattractant protein-1 (MCP-1)**, AI and, 166–172
- Monocytes**, in tissue factor expression, 726–738
- Morbidity**  
 in chronic dialysis, predictors of, 69–79

- dialyzer membrane change and, 606–610  
prolonged hypoglycemia in ESRD, 500–505  
*Morinda citrifolia*, hyperkalemia and, 310–311
- Mortality**  
breast cancer, 327–329  
dialyzer membrane change and, 606–610  
ESRD, in comparison of renal replacement therapy effectiveness, 653–659  
hyperphosphatemia/hyperparathyroidism and, 1226–1237  
prediction  
in chronic dialysis, 69–79  
C-reactive protein and, 469–476  
in ESRD with sleep disorders, 1052–1061  
prolonged hypoglycemia in ESRD, 500–505  
in renovascular disease, DD genotype and, 211–215  
reuse-associated, disease severity, HCT and, 244–249  
from septicemia, in diabetic vs. nondiabetic patients, 282–292  
of uremic patients after star fruit ingestion, 189–193
- MPO-ANCA** (myeloperoxidase-antineutrophil cytoplasmic autoantibody), angitis/nephritis associated with, 889–895
- MRA** (magnetic resonance angiography), of access recirculation in native fistula, 529–532
- MRI.** See Magnetic resonance imaging
- Mucormycosis**, renal, in HIV-infected patient, 5:E24
- Multivariate analysis**, long-term cyclosporine in transplant patients, 1135–1143
- Murine model**  
knockout. *See Knockout mice*  
of polycystic kidney disease, probucol effects on, 221–226
- Muscle infarction**, diabetic, in dialysis patients, 1212–1216
- Mycophenolate mofetil**, immunosuppression, renal function and, 333–346
- Myeloperoxidase** (MPO), in anti-GBM-associated glomerulonephritis, 954–957
- Myeloperoxidase-antineutrophil cytoplasmic autoantibody** (MPO-ANCA), angitis/nephritis associated with, 889–895
- Myocardial infarction**  
dialysis outcome after, 1217–1219  
with ESRD, survival and, 1044–1051
- Myocardial ischemia**, in hemodialysis and ultrafiltration, 819–826
- Myocardial necrosis**, in Henoch-Schönlein purpura, 319–322
- Myocardial vasculitis**, in Henoch-Schönlein purpura, 319–322
- L-NAME**, effects on polycystic rat model, 930–936
- National Kidney Foundation**  
affiliates, 79, S1:49–68  
Constituent Councils, S1:78
- Dialysis Outcomes Quality Initiative**, 77, S1:69–75
- Family Focus Program**, S1:77  
50th anniversary, S1:1–2  
history, S1:3–18  
of professional councils, S1:19–30  
of research efforts, S1:31–36
- KEEP**, S1:78
- Office of Scientific and Public policy**, S1:79
- PARADE**, S1:78
- physician membership, S1:78–79
- private sector relationship, S1:79
- professional councils, 78, S1:19–30
- research programs, 79, S1:31–36
- restructuring, S1:81–89  
in 21st century, S1:93–96
- Transplant America**, S1:77
- US Transplant Games**, S1:77–78
- volunteers, S1:79–80
- Neoplasms**, cross-cultural classification comparisons, 165
- Nephrectomy**, laparoscopic, for ESRD in ADPKD, 720–725
- Nephrocalcinosis**, IgE, with renal tubular acidosis and vascu-litis, 941–949
- Nephrocystin**, in juvenile nephronophthisis, 44–51
- Nephrolithiasis**, for familial microscopic hematuria, 141–145
- Nephrologist**  
technological changes and, 978–979  
ultrasonography and, 1021–1039
- Nephrology**, in 21st century, S1:90–92
- Nephronophthisis**, juvenile, clinical/molecular heterogeneity of, 44–51
- Nephropathy**  
atherosclerotic, in atherosclerotic renovascular disease, 573–587  
herbal medicine and, 330–331
- Nephroprotection**, of ACE inhibitors, 1155–1165
- Nephrotic proteinuria**, total body protein synthesis and, 1149–1154
- Nephrotic syndrome**  
persistent, ACE inhibition in, 381–391  
remission, after removal of localized Castleman's disease, 1207–1211  
in renal failure prediction, in IgA nephropathy, 13–20  
whole-body valine flux in, 1149–1154
- Nephrotoxicity**, of immunosuppressive drugs, 333–346
- Neurological symptoms**, after star fruit ingestion, 189–193
- Neutrophil granules**,  $\beta_2$ -microglobulin and lactoferrin content in renal failure, 1117–1126
- Nicardipine**, for pediatric hypertensive emergencies, 5:E20
- Nitric oxide**, in polycystic kidney disease pathogenesis, 930–936
- Noncompliance**  
with CAPD, in US vs. Canada, 506–514  
with dialysis exchanges in peritoneal dialysis, 1104–1110
- Nondiabetic renal disease**  
ACE effects in, 695–707  
nephropathy, antihypertensive therapy for, 4: liv–lvi  
proteinuria and, S1:97–105
- Noni juice**, hyperkalemia and, 310–311
- Nonsteroidal anti-inflammatory drugs** (NSAIDs), nephrotoxi-city, 937–940, 976–977
- Normeperidine neurotoxicity**, hemodialysis for, 146–149
- Nosocomial infections**, in chronic hemodialysis, risk factors for, 1083–1089
- NSAIDs** (nonsteroidal anti-inflammatory drugs), nephrotoxi-city, 937–940, 976–977
- Nutritional counseling**  
maintenance dialysis

- adult, S2:46–47  
pediatric, S2:118–119  
for nondialyzed chronic renal failure, S2:62–63
- Nutritional status  
assessment, pediatric guidelines, S2:105–106  
dialysis dose, mortality risk and, 80–88  
measures  
for hemodialysis maintenance, S2:17–19  
for nondialyzed CRF patients, S2:56–57
- Nutritional support, for maintenance dialysis  
adult, S2:48–50  
pediatric, S2:120–121
- Obesity  
in chronic renal failure, calcified arterioles and subcutaneous infarcts in, 588–597  
normotensive, glomerular filtration rate in, 1144–1148
- Obstructive nephropathy, cross-cultural classification comparisons, 157–165
- Obstructive uropathy, ultrasonography, 1021–1039
- Ochrobactrum anthropi* bacteremia, in hemodialysis patient, 6:E30
- Ondansetron, for uremic pruritus, in hemodialysis, 827–831
- Organ distribution, for renal transplantation, S1:153–159
- Osteitis fibrosa, 22-oxacalcitriol for, 458–464
- Outcome  
of acute renal failure in older adults, 433–447  
body size, dialysis dose and, 80–88  
Dialysis Outcomes Quality Initiative, S1:69–75  
of dialysis patients, after acute myocardial infarction, 1217–1219  
dialyzer reuse, disease severity, hematocrit level and, 244–249  
evaluation, of HD vs. PD patients, 293–300  
fatal, after star fruit ingestion in uremic patients, 189–193  
IgA nephropathy, histological grading system and, 392–400  
intermittent hemodialysis variables and, 980–991  
long-term, cyclosporine monotherapy in transplant patients and, 1135–1143  
measures, URR vs. Kt/V for, 598–605  
of mild renal failure, after cardiac valve surgery, 1127–1134  
peritoneal dialysis, noncompliance pattern with dialysis exchanges and, 1104–1110  
predictors  
in chronic dialysis patients, 69–79  
in lupus nephritis, 904–914  
in primary hypertension, smoking and, 767–769  
renal rehabilitation and, S1:141–147  
septicemia in diabetic vs. nondiabetic hemodialysis patients and, 282–292  
subdural hematoma in ADPKD and, 40–43
- 22-Oxacalcitriol, for osteitis fibrosa, 458–464
- Oxidant stress, advanced glycation end products and, 365–380
- Pain  
management, in ADPKD, 770–772  
puncture-related, dialysis cannula design and, 624–628
- P-ANCA glomerulonephritis, familial case report, 5:E23
- Pancreas transplants, for diabetic nephropathy, 1238–1241
- Pancytopenia, with HCV-related cryoglobulinemia, splenectomy for, 1186–1192
- PARADE, S1:78
- Parathyroid glands, sonographically detected, pulsed-dose calcitriol resistance and, 465–468
- Parathyroid hormone  
recombinant human growth hormone, for pediatric maintenance dialysis and, S2:122–123  
secretion, 22-oxacalcitriol suppression of, 458–464
- Parvovirus B19  
DNA, in kidney tissue in FSGS, 1166–1174  
infection, after acute glomerulonephritis, 6:E31
- Patient assessment, of chronic peritoneal dialysis, 638–643
- Patient self-reports, on renal rehabilitation, S1:141–147
- Pauci-immune necrotizing lupus nephritis, with microangiopathy, 1193–1206
- Pediatric patients. *See Children*
- PEM. *See Protein-energy malnutrition*
- Periodic limb movements in sleep (PLMS), with ESRD, mortality predictors for, 1052–1061
- Peripheral neuropathy, lead-induced, in dialysis patient, 963–968
- Peripheral vascular disease, progressive treatment in diabetics, for septicemia prevention, 282–292
- Peritoneal calcification, after long-term CAPD, 761–766
- Peritoneal dialysis (PD)  
adequacy. *See Adequacy, peritoneal dialysis*  
automated, noncompliance pattern with dialysis exchanges, 1104–1110  
catheters. *See Catheters, peritoneal dialysis*  
chronic  
dietary protein intake, S2: 42–43  
predictors of poor outcome in, 69–79  
quality of care assessment for, 638–643  
for chronic renal disease, with cardiovascular disease, S1:117–131  
continuous ambulatory. *See Continuous ambulatory peritoneal dialysis*  
for ESRD, in future, S1:106–116  
fluid. *See Peritoneal dialysis fluid*  
IGF-1 improvement of renal function after, 150–153  
iron dextran therapy and, 3  
in Japan, multicenter cross-sectional study of, 515–525  
noncompliance pattern with dialysis exchanges, 1104–1110  
outcome, after star fruit ingestion, 189–193  
pediatric, Tenckhoff vs. Cook catheters for, 1111–1116  
quality of life evaluation, vs. HD, 293–300
- Peritoneal dialysis facility, quality of care, patient assessment of, 638–643
- Peritoneal dialysis fluid (PDF), bicarbonate-lactate and bicarbonate buffered, macrophage function and, 112–121
- Peritoneal macrophage, in vivo function, bicarbonate/lactate vs. bicarbonate buffered PDF and, 112–121
- Peritonitis, CAPD, cytokine profile changes in, 644–652
- Permcath priming, heparin vs. rTPA for, 130–136
- Pharmacoeconomics, of IV iron products, 9–10
- Pharmacoeconomics access, for ESRD, in future, S1:106–116

- Pharmacokinetics, tacrolimus, for kidney transplant recipients, 660–666
- Phenytoin overdosage, charcoal hemoperfusion for, 323–326
- Phosphate binders, for hyperphosphatemia in dialysis, 1226–1237
- Phosphatidylcholine-superoxide dismutase, protection of  $\alpha_3$ -integrin-mediated podocyte shape in puromycin aminonucleoside nephrosis, 1175–1185
- Physical function, in hemodialysis patients, self-reports on, 482–492
- Physicians, subjective judgment on peritoneal dialysis dose, 515–525
- PKD1 locus, ADPKD with Marfan syndrome in kindred and, 753–760
- Plasminogen activator inhibitor-1 (PAI-1) expression, in crescentic glomerulonephritis, 726–738 in progressive glomerulosclerosis, 179–188
- Polyclastic kidney disease (PKD) autosomal dominant. *See* Autosomal dominant polycystic kidney disease experimental L-NAME effects on, 930–936 probucol effects on, 221–226 renal mass reduction effects in, 923–929
- Polymerase chain reaction (PCR), detection of parvovirus B19DNA in FSGS kidney tissue, 1166–1174
- Polymorphonuclear leukocytes (PMNLs)  $\beta_2$ -microglobulin, in renal failure patients, 1117–1126 lactoferrin, in renal failure patients, 1117–1126
- Polymyalgia rheumatica, secondary amyloidosis in, 137–140
- Polysulfone membrane, serum albumin levels and, 606–610
- Polytetrafluoroethylene graft (PTFE), thrombosis, antiphospholipid antibodies and, 796–801
- Postinfectious glomerulonephrosis, 1:xvi–xlvii
- Potassium excretion impairment, in acute renal failure, 871–877 in star fruit, 189–190
- Prealbumin, maintenance dialysis nutritional status and, S2:22
- Prescription for peritoneal dialysis, vs. delivered dosage, 515–525
- Presensitization, in spousal-donor kidney transplantation, 667–673
- Primary renal diseases, world-wide classification differences, 157–165
- Probucol, effects on murine PKD model, 221–226
- Prognosis for chronic dialysis, 69–79 IgA nephropathy histological grading system and, 392–400 tubular grading and, 13–20 renal cortical necrosis, magnetic resonance imaging and, 745–748
- Progression of IgA nephropathy, CRP and C3 levels and, 21–28 of renal disease proteinuria in, S1:97–105
- Proliferative lesions, in IgA nephropathy, early corticosteroids for, 194–201
- Prospective cohort study, chronic dialysis outcome prediction, 69–79
- Protease-activated receptor, in crescentic glomerulonephritis, 726–738
- Protein binding, in phenytoin overdosage, charcoal hemoperfusion for, 323–326
- Protein catabolic rate, dialyzer membrane change and, 606–610
- Protein-energy malnutrition (PEM) causes, in CRF, S2:9 K/DOQI guidelines for adults, S2:17–19 for prevention/treatment, S2:9–10 research recommendations, S2:17–19
- Protein-energy nutritional status, pediatric assessment guidelines, S2:105–106
- Protein equivalent of nitrogen appearance determination, S2:71–74 nutritional status in maintenance dialysis, S2:28–29
- Protein intake expression/calculation, from dietary interviews/diaries, S2:68–69 for maintenance dialysis during acute illness, S2:51–53 pediatric, S2:114–115 for nondialyzed chronic renal failure, S2:58–59
- Proteinuria. *See also* Albuminuria in adaptation to renal mass reduction in polycystic rat, 923–929
- ADPKD progression and, 547–550 antihypertensive therapy for hypertension in ADPKD and, 427–432 diagnosis, fluorescent dye method vs. radioimmunoassay for, 739–744
- ESRD progression risk, ACE inhibition and, 381–391 in heme oxygenase-1 deficiency, tubulointerstitial injury and, 863–870
- in IgA nephropathy early corticosteroids for, 194–201 prognosis and, 13–20 progression to terminal failure, ACE inhibition and, 202–210
- in progressive renal disease, S1:97–105 renal biopsy for, 448–457 smoking-related augmentation, in hypertension, 687–694 with *Staphylococcus aureus* pneumonia, 354–359 in type 2 diabetes, familial clustering of, 708–712
- Proteinuric nephropathy, progression and response to treatment, 1155–1165
- Pruritus, uremic, in hemodialysis, ondansetron for, 827–831
- Psychological well-being, from renal replacement therapies, comparison of, 629–637
- Psychosocial factors, in end-stage renal disease, S1:132–140
- Pulmonary hemorrhage, in anti-GBM-associated glomerulonephritis, 954–957
- Pulmonary renal syndrome, MPO-ANCA-associated, 889–895
- Puromycin aminonucleoside nephrosis, SOD protection of  $\alpha_3$ -integrin-mediated podocyte shape in, 1175–1185

- Quality of life  
for chronic dialysis patients, 69–79  
comparisons, of renal replacement therapies, 629–637  
in end-stage renal disease, S1:132–140  
for hemodialysis patients, self-reports on, 482–492  
Short Form 36 evaluation, in HD vs. PD patients, 293–300
- Quinton Permcath, priming, heparin vs. rTPA for, 130–136
- Race  
idiopathic focal segmental glomerulosclerosis and, 878–883  
renal replacement therapy outcomes in women and, S1:148–152  
variations  
in ADPKD, 35–39  
of blood pressure in hemodialysis, 257–265  
of mortality risk with dialysis dose/body size, 80–88
- Ramipril, kidney disease progression and, 1155–1165
- Randomized placebo-controlled trials, of ACE inhibition in diabetic vs. nondiabetic renal disease, 695–707
- Ras proteins, progression of polycystic kidney disease and, 221–226
- Rats  
hypertensive fawn-hooded, ACE inhibition effects on, 202–210  
with polycystic kidney disease, L-NAME effects on, 930–936
- Reactive oxygen species, protection of  $\alpha_3$ -integrin-mediated podocyte shape in puromycin aminonucleoside nephrosis, 1175–1185
- Recirculation  
despite adequate access flow, 529–532  
measurement, ultrasound method for, 477–481
- Recombinant human erythropoietin. *See* Erythropoietin, recombinant human
- Recombinant human growth hormone, for pediatric maintenance dialysis, S2:122–123
- Recombinant immunoblot assay, HCV serotyping, 832–838
- Recombinant tissue plasminogen vs. heparin, for Quinton Permcath priming, 130–136
- Recumbent length measurement, S2:124
- Renal ablation, ADPKD acceleration and, 923–929
- Renal artery stenosis, atherosclerotic renovascular disease and, 573–587
- Renal biopsy  
acute renal failure  
in elderly, 433–447  
with interstitial nephritis in AIDS, 557–561  
allograft dysfunction, 997–1001  
current indications, 448–457  
in elderly, 433–447, 544–546  
Fanconi syndrome, 777–781  
fibrillary deposits, differential diagnosis of, 173–177  
procedure, 451–452  
*Staphylococcus aureus* pneumonia, 354–359
- Renal cells, adaptation to hypertonicity, 6:xlvii–l
- Renal cortical necrosis, magnetic resonance imaging features, 745–748
- Renal cyst, digital reconstruction, 216–220
- Renal dialysis registries, world-wide classification differences in, 157–165
- Renal dietitian, role of, S2:70
- Renal Exercise Demonstration Project, 482–492
- Renal failure. *See* Acute renal failure; Chronic renal failure; End-stage renal disease
- Renal failure index, in differentiation of prerenal azotemia from ATN, 713–719
- Renal fibrosis  
AI and PAI-1 in, 179–188  
maximal reduction of angiotensin in, 773–776  
renin-angiotensin system in, 773–776
- Renal infarction, cocaine-induced, 788–789
- Renal outer medullary potassium channel, in acute renal failure, 871–877
- Renal plasma flow, in overweight normotensive humans, 1144–1148
- Renal rehabilitation, obstacles, progress and future prospects, S1:141–147
- Renal replacement therapy. *See also* Hemodialysis; Peritoneal dialysis; specific types of renal replacement therapies  
advanced glycation end products and, 374–375  
body scaling, Kt/V and, 306–309  
continuous, regional citrate anticoagulation in, 802–811  
evaluating effectiveness of, 633–659  
indications, for nondialyzed CRF patients, S2:64–65  
outcomes, in black vs. white women, S1:148–152  
quality of life, comparison studies of, 629–637  
sexual dysfunction after, 845–851
- Renal transplantation  
access, for lupus nephritis end-stage renal disease, 915–922  
bone loss, 1,25-dihydroxyvitamin D<sub>3</sub> and calcium carbonate effects on, 227–236  
for chronic renal disease, with cardiovascular disease, S1:117–131  
complications, membranoproliferative glomerulonephritis, 539–542, 749–752  
cyclosporine monotherapy, long-term results of, 1135–1143  
for ESRD, in future, S1:106–116  
in evaluating therapeutic effect on ESRD survival, 653–659  
history of, S1:153–159  
kidney transplant, renal biopsy for, 448–457  
pediatric, abnormal 24-hour blood pressure patterns, 681–686  
recipients  
abbreviated tacrolimus AUC monitoring for, 660–666  
ACEi and AT II antagonists for, 58–63  
subclinical cryoglobulinemia in, 52–57  
rejection, 674–680  
sexual dysfunction after, 845–851  
spousal-donor, antirejection therapy target for, 667–673  
thrombocytopenia after, 537–538  
ultrasonography, 1021–1039
- Renal tubular acidosis, with vasculitis and IgE deposits, 941–949
- Renin-angiotensin system  
in ESRD progression with IgA nephropathy, ACE genotype and, 896–903  
in renal fibrosis, 773–776

- Renovascular disease**  
  atherosclerotic, epidemiology/clinical manifestations of, 573–587  
  survival, ACE gene polymorphism and, 211–215
- Renovascular hypertension**, in atherosclerotic renovascular disease, 573–587
- Residual renal function**, outcome prediction in chronic dialysis, 69–79
- Revascularization**, for atherosclerotic renovascular disease, 573–587
- Seasonal variations**, of blood pressure in chronic hemodialysis, 812–818
- Self-report questionnaires**, on sexual dysfunction after renal replacement therapy, 845–851
- Septicemia**, in diabetic vs. nondiabetic hemodialysis patients, 282–292
- Serotonin-receptor antagonist**. *See also* Ondansetron  
  for uremic pruritus, in hemodialysis, 827–831
- Serotyping strip immunoblot assay**, hepatitis C virus, 832–838
- Sexual dysfunction**, after renal replacement therapy, 845–851
- SGA**. *See Subjective global nutritional assessment*
- Short Form 36-item questionnaire**  
  of HD vs. PD patients, 293–300  
  physical function in hemodialysis patients and, 482–492
- Skeletal frame size**, estimation of, 77, S2:76
- Skinfold thickness**, measurement of, S2:77–84
- Skin infarction**, in chronic renal failure, 588–597
- SLE**. *See Systemic lupus erythematosus*
- Sleep disorders**, in ESRD  
  hemodialysis and, 1221–1223  
  mortality predictors for, 1052–1061
- Smoking**  
  renal insufficiency in essential hypertension and, 687–694  
  renal outcome in primary hypertension and, 767–769  
 $\alpha$ -Smooth muscle actin, in IgA nephropathy, after corticosteroid therapy, 194–201
- Social support**, for end-stage renal disease, S1:132–140
- Splenectomy**, glomerulopathy of type II mixed cryoglobulinemia and, 1186–1192
- Staphylococcus aureus pneumonia**, in adolescent, 354–359
- Star fruit ingestion**, by uremic patients, fatal outcome from, 189–193
- Step-down unit patients**, health care team demands of, 1061–1067
- Steroid therapy**, adjuvant, for long-term cyclosporine monotherapy, 1135–1143
- Subcutaneous infarction**, in chronic renal failure, 588–597
- Subdural hematoma**, in ADPKD, 40–43
- Subendothelial deposits**, in glomerulonephritis after parvovirus B19 infection, 6:E31
- Subjective global nutritional assessment (SGA)**  
  maintenance dialysis, S2:30–31  
  methods, S2:75
- Sulfonylurea-induced hypoglycemia**, in diabetics with ESRD, 500–505
- Sulfosalicylic acid urinary albumin measurement**, vs. fluorescent dye method, 739–744
- Survival**  
  ESRD  
    after acute myocardial infarction, 1044–1051  
    evaluating effectiveness of renal replacement therapy, 653–659  
    urea reduction ratio and, 598–605
- Systemic lupus erythematosus (SLE)**  
  glomerulonephritis and thrombotic microangiopathy in, 1193–1206  
  with allograft failure, 1242–1247  
  nephritis, outcome predictors in, 904–914  
  peptide autoepitopes for nucleosome-specific T cells, 992–996
- Tacrolimus**  
  abbreviated AUC monitoring, for kidney transplant recipients, 660–666  
  long-term post-transplant, for MPGN prophylaxis, 539–542  
  nephrotoxicity, 333–346
- Takayasu's arteritis**, with intrarenal vessel involvement, 950–953
- Taxonomy**, 638–643
- TBW (total body water)**, mortality of dialysis patients and, 80–88
- T-cells**  
  activation  
    in ESRD, hemodialysis initiation and, 611–616  
    vitamin E-coated dialyzer membranes and, 95–104  
  in renal disease in HIV-transgenic mice, 408–417
- Tenckhoff catheter**  
  malposition, repositioning techniques for, 301–305  
  for pediatric peritoneal dialysis, 1111–1116
- T helper 1**, circulating levels, in hemolytic uremic syndrome, 29–34
- Thiazide diuretics**, for familial microscopic hematuria, 141–145
- Thin basement membrane disease**, secondary to hematuria and tubular necrosis, 533–536
- Thrombectomy**, for renal allograft vein thrombosis, 5:E21
- Thrombin**, as pathogenic mediator of crescentic lesions, 726–738
- Thrombin antibodies**, vascular access thrombosis and, 796–801
- Thrombin receptor expression**, in crescentic glomerulonephritis, 726–738
- Thrombocytopenia**, post-transplant, 537–538
- Thrombosis**  
  predictive accuracy of graft blood flow decrease and, 1089–1095  
  vascular access, antiphospholipid antibodies and, 796–801
- Thrombotic microangiopathy**, with glomerulonephritis in SLE and lupus-like syndrome, 1193–1206
- Timing**, of intermittent hemodialysis, outcome and, 980–991
- Tissue factor expression**, in crescentic glomerulonephritis, 726–738
- T lymphocytes**. *See* T-cells
- Total body protein synthesis**, nephrotic proteinuria and, 1149–1154

- Total body water (TBW), mortality of dialysis patients and, 80–88
- Total parenteral nutrition (TPN), in maintenance dialysis, S2:49–50
- Toxic nephropathy, cross-cultural classification comparisons, 157–165
- TPN (total parenteral nutrition), in maintenance dialysis, S2:49–50
- Transferrin, serum, S2:86
- Transforming growth factor- $\beta$ 1  
  All and, 166–172  
  circulating levels, in hemolytic uremic syndrome, 29–34  
  during peritonitis CAPD, 644–652
- Transgenic mice, T-cell role in HIV-associated renal disease, 408–417
- Transplantation  
  kidney. *See Renal transplantation*  
  pancreas, for diabetic nephropathy, 1238–1241
- Transplant registries, world-wide classification differences in, 157–165
- Triceps skinfold thickness  
  by age, S2:127  
  measurement method, S2:125
- Tubular grading, IgA nephropathy prognosis and, 13–20
- Tubular necrosis, with thin basement membrane disease, 533–536
- Tubular obstruction, in glomerulocystic kidney disease, digital reconstruction of, 216–220
- Tubulointerstitial disease, ultrasonography, 1021–1039
- Tubulointerstitial injury, in heme oxygenase-1 deficiency, 863–870
- Ultrafiltration, cardiac and hemodynamic effects of, 819–826
- Ultrasound  
  dilution technique, for recirculation measurement, 529–532  
  Doppler. *See Doppler ultrasound*  
  of microembolic signals in HD access, 526–528  
  parathyroid gland, pulsed-dose calcitriol resistance and, 465–468  
  principles, review of, 1021–1039  
  renal failure, 1021–1039
- Uninephrectomy, ADPKD acceleration and, 923–929
- Urea filtration rate/volume. *See Kt/V*
- Urea kinetic modeling, pediatric guidelines, S2:109–110
- Urea reduction ratio (URR)  
  citrate vs. acetic dialysate and, 493–499  
  improvement with two parallel dialyzers, 266–274  
  mortality of dialysis patients and, 80–88  
  mortality prediction, for ESRD with sleep disorders, 1052–1061  
  as outcome-based measure of hemodialysis dose, 598–605
- Uremia. *See also End-stage renal disease*  
  complications, aminoguanidine prevention of, 365–380  
  effect of hemodialysis initiation on, 611–616  
  neutrophil  $\beta_2$ -microglobulin and lactoferrin content in, 1117–1126
- Uric acid crystals, in familial microscopic hematuria urine sediment, 141–145
- Urinary tract infection  
  cocaine-induced, 789  
  nosocomial in chronic hemodialysis, risk factors for, 1083–1089
- URR. *See Urea reduction ratio*
- USRDS registry, cross-cultural comparison of renal disease classifications, 157–165
- Usual body weight, percentage of, S2:76
- Valine whole-body flux, in nephrotic syndrome, 1149–1154
- Vancomycin, for chronic hemodialysis, 64–68
- Vascular access. *See also Catheters; Graft*  
  failure, ultrasound surveillance methods for, 477–481  
  fistula  
    facility specific standardized ratio calculation for, 275–281  
    microembolic signals in, 526–528  
  flow adequacy, access recirculation and, 529–532  
  microembolic signals in, 526–528  
  monitoring, ultrasound dilution technique for, 529–532  
  puncture, dialysis cannula design and, 624–628  
  recirculation, despite adequate access flow, 529–532  
  septicemia risk in diabetic vs. nondiabetic hemodialysis patients, 282–292  
  thrombosis, antiphospholipid antibodies and, 796–801  
  variability, standardized ratios of, 275–281
- Vascular calcification risk, with hyperphosphatemia and hyperparathyroidism in dialysis, 1226–1237
- Vascular disease, ultrasonography, 1021–1039
- Vascular graft occlusion, predictive accuracy of graft blood flow decrease and, 1089–1095
- Vasculitis  
  in elderly with acute renal insufficiency, 433–447  
  intrarenal, in Takayasu's arteritis, 950–953  
  with renal tubular acidosis and IgE deposits, 941–949
- Verotoxin-producing *Escherichia coli*, hemolytic uremic syndrome and, 29
- Vitamin B<sub>12</sub>, in ultrafiltrate, for assessment of low-flux membrane permeability, 839–844
- Vitamin D receptor, resistance to calcitriol for secondary hyperparathyroidism, 465–468
- Vitamin D supplementation, for hyperphosphatemia/hyperparathyroidism in dialysis, 1226–1237
- Vitamin E-coated dialyzer membranes, T-cell activation, cytokine induction and, 95–104
- Vitamin requirements, pediatric maintenance dialysis, S2:116–117
- Waist/hip ratio, GFR in normotension and, 1144–1148
- Weight. *See Body weight*
- Whole-body turnover, of valine in nephrotic syndrome, 1149–1154
- Women. *See also Gender differences*  
  renal replacement therapy outcomes, race and, S1:148–152
- Wrist drop, in lead-induced peripheral neuropathy, 963–968
- Xenotransplantation, for ESRD in future, S1:106–116

